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CHAPTER 1 “ROLE OF INFLAMMATION IN THE PATHOGENESIS OF
DIABETIC RETINOPATHY”
1.1 Diabetic Retinopathy
Diabetic retinopathy (DR) is a visually debilitating eye disease that affects
patients diagnosed with diabetes mellitus (DM). In brief, diabetes is a chronic,
metabolic disease resulting in high blood glucose levels in the body. As of 2014,
it was estimated that 387 million people are diabetic worldwide (Update 2014).
This is expected to increase by 55% in the next 20 years, reaching epidemic
levels by 2035 (Fig. 1). There are three major types of diabetes: type 1, type 2
and gestational diabetes.
Type 1 diabetic mellitus (T1DM) is an autoimmune disease, during which
the host immune system mistakenly attacks pancreatic beta cells, thus
rendering them incapable of producing insulin. T1DM is referred to as “insulindependent” associated, in large part, with genetic risk factors. On the other
hand, multifactorial causes drive type 2 diabetic mellitus (T2DM) which include
obesity, unhealthy diet, age, and family history resulting in reduced sensitivity
to insulin among patients. T2DM diabetes is considered “non-insulin-dependent”
and affects roughly 90% of patients diagnosed with DM [1].
Diabetic retinopathy is known to be the leading cause of irreversible
blindness among people of working age in the United States with more than
10,000 new cases annually [2]. This disease progresses through four stages,
which feature a number of pathological events associated with the retina. Early
stage DR is called background or non-proliferative diabetic retinopathy (NPDR);
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Figure 1. Current and projected cases of diabetes worldwide from 2014 –
2035. Source: International Diabetes Federation.
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patients are typically asymptomatic, but retinal blood vessels become damaged
and begin to leak fluid. NPDR features microaneurysms, retinal hemorrhages
(flame, dot), hard exudates (cholesterol/fat deposits from vasculature), macular
ischemia, and macular edema (the most common cause of vision loss in
diabetes) (www.geteyesmart.org/eyesmart/diseases/diabetic-retinopathy) (Fig.
2). These latter changes are considered moderate to severe NPDR. Most of the
time, vision is still not affected with mild NPDR, except in cases where macular
edema occurs because swelling of the macula interferes with clear vision
processing.
Proliferative diabetic retinopathy (PDR) mainly develops as a result of
retinal ischemia. Once blood vessels begin to close and reduce blood flow, the
retina tries to compensate through neovascularization. During the advanced
stages of PDR, blood vessels expand and grow (Fig. 2). These new vessels are
abnormal however; they are more fragile and can be associated with scar tissue.
As a result, the new vessels are prone to bleeding into the vitreous and the scar
tissue can cause the retina to wrinkle or detach. Both of these situations result
in severe vision loss affecting both central and peripheral vision. In addition,
neovascularization can result in secondary glaucoma (neovascular glaucoma)
[3].
Despite the high incidence of DR and its expected increase to epidemic
levels in the next couple of decades, no existing treatments can significantly
reverse either early or late stage DR. T1DM typically develop early diagnostic
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Figure 2. Fundus images demonstrating the different grades of diabetic
retinopathy. Abbreviations: PDR, proliferative diabetic retinopathy; NPDR, nonproliferative diabetic retinopathy; PLM, previous laser marks. Source: El-Bab MF
et al., Clin Ophthalmol (2012).
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DR symptoms after roughly five years of onset, advancing into various degrees
of retinopathy during the subsequent 20 years. In contrast, T2DM patients
commonly present signs of early stage retinopathy concurrent with the initial
diagnosis of diabetes, of which 60% will develop progressing degrees of
retinopathy [4]. Strict control of blood sugar levels still remains the most
effective approach to slow the onset of DR. As a result, mild or moderate NPDR
is only monitored, while treatment is reserved for PDR. Current treatment
options for the later stages include laser surgery and pan-retinal
photocoagulation (PRP). Laser surgery is typically used to treat macular edema,
PDR and neovascular glaucoma. PRP is aimed at shrinking new vessels and
inhibiting further formation. This procedure also helps to reduce the chances for
vitreous bleeding or retinal detachment. Vitrectomy is performed on patients
who have had a vitreous hemorrhage; it removes both the blood and scar tissue
in an effort to restore normal retinal function. The aforementioned procedures
are invasive and have adverse side effects including reduced color vision, fovea
damage, and Bruch’s membrane rupture. In light of the role of angiogenesis in
the DR pathology, ophthalmologists are applying anti-angiogenic medications
as well [5]. Particularly, anti-VEGF has revolutionized the treatment of diabetic
macular edema. Ranibizumab currently has FDA approval, while bevacizumab
is commonly used off-label and FDA approval is pending for afilbercept [6].
However, even anti-VEGF treatment has limited therapeutic outcomes as not
all patients respond and it can cause many devastating complications, as well.
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age-related

macular

degeneration [7]. Therefore, the development of more effective treatment
modalities for both early and late stages of DR is of major concern.
1.2 Pathogenesis of DR
As stated, patients rarely develop clinical symptoms during early stage DR
[4]; while the more advanced and complicated progressive stages feature
hallmarks such as stimulated release of VEGF, retinal edema, retinal
microaneurysms,

capillary

nonperfusion

and

degeneration

with

neovascularization, and dysregulated neural function and structure [8-12]. In
order to develop effective treatments, it is essential to go beyond the clinical
manifestations of disease and understand the events associated with the
development and progression of DR. In fact, it has been through better
understanding of the biochemical events that take place that led to the
development of anti-angiogenic treatments. To this end, the current project
seeks to focus on the role of inflammation in driving the cellular and molecular
events associated with DR to identify therapeutic points of intervention leading
to improved disease outcome.
Extensive research using animal models has allowed for the association of
clinical symptoms with different pathological events known to occur during the
development and progression of DR (Fig. 3). Firstly, oxygen metabolism is an
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Figure 3. Diagrammatic representation of key factors known to be involved in
DR pathogenesis. Source: Robinson R et al., Disease Models & Mechanisms
(2012).
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important component of cellular homeostasis. Under normal physiological
conditions, low levels of reactive oxygen species (ROS) are produced by the
mitochondrial electron transport chain – up to 5% of oxygen that enters into this
reaction [13]. Cytochrome P450, NADPH oxidase and nitric oxide synthases
also contribute to this normal cellular function. During diabetes however, the
ROS scavenging system is impaired, resulting in unbalanced, excessive ROS
levels termed “oxidative stress”. Kowluru and Chan have described possible
causes such as auto-oxidation of glucose, shifted redox balance, reduced
glutathione (GSH), and impaired superoxide dismutase (SOD), leading to
further enhanced ROS production, vascular inflammation, protein/lipoprotein
oxidation and overall impaired cellular homeostasis [13].
Protein kinase C (PKC) comprises a family of serine/threonine kinases
containing a Ca2+ and/or diacylglycerol (DAG) binding domain and takes part
in various intracellular pathways when phosphorylated and translocated. Under
a high glucose environment, DAG is up-regulated and then stimulates activation
of the PKC pathway, which is associated with multiple cardiovascular
abnormalities in diabetic mellitus. It has been reviewed by Das Evcimen and
King that the DAG-PKC pathway affects the vascular system in multiple aspects,
including endothelial permeability, cell growth, angiogenesis, cytokine
metabolism and leukostasis [14].
Advanced glycation end products (AGEs) is another pathogenic factor;
these modified proteins/lipids are up-regulated and accumulated during DR.
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AGEs contribute to the vasculopathy associated with DR. Regarding
inflammation, the most important pathway is the receptor for advanced
glycation end products (RAGE) pathway, in which AGE-modified proteins, such
as Nε-carboxy-methyl-lysine (CML) interact with the vascular endothelium via
the RAGE receptor, thus up-regulating NF-κB and its target genes, proinflammatory cytokines such as VEGF and TNF-α [15]. This series of
pathophysiological alterations will proceed to cross-linking and result in
activation of cytokines, cellular dysfunction and apoptosis of vascular and
neuronal cells, which will further destroy healthy retinal microvascular
endothelial cells and compromise the blood-retinal barrier, ultimately leading to
vascular permeability. It is important to note that all of the above-mentioned
pathogenic pathways at least partially contribute to the development of local
inflammation in the retina, which is the major interest in this series of studies.
1.3 Inflammation
Inflammation is, for the most part, a protective host response that includes
chemotaxis of immune cells and activation of various molecular mediators, such
as cytokines and chemokines. During this process, both infiltrated immune cells
(macrophages and PMN) and local residential cells secretes inflammatory
mediators: chemokines, interferons (IFN), interleukins (IL) and tumor necrosis
factors (TNF) and further drives progress of inflammation. The activation of the
endogenous pro-inflammatory cytokine network is counterbalanced by the
subsequent generation of anti-inflammatory and pro-resolving agents. Despite
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the beneficial role of pro-inflammatory factors in host defense, their sustained
production can potentiate chronic inflammation leading to deleterious
pathological conditions [16, 17]. As a result, inhibition of pro-inflammatory
mediators by endogenous molecules such as anti-inflammatory molecules and
specialized pro-resolving mediators (SPM) typically occurs during the normal
progression of a healthy inflammatory response. If acute inflammation persists,
sustains and remains unresolved, chronic inflammation will develop. In any
case, a state of chronic inflammation results in disease pathogenesis.
Inflammation has been found to be associated with DR as early as the
1960’s when it was discovered that diabetic patients, who were administered
salicylates for rheumatoid arthritis, demonstrated a lower incidence of
retinopathy [18]. However, the immune response and pro-/anti-inflammatory
mediators have only recently received considerably more attention. Leukostasis,
which is the excessive influx of leukocytes into the retina leading to obstruction
of blood vessels and increased blood viscosity, has been found to be classically
associated with DR. Other evidence implicating the participation of an activated
inflammatory response includes the upregulation of adhesion molecule ICAM1 and its ligand, CD18, located on retinal cells and neutrophils, respectively [1922]. In addition, studies have described the involvement of potent proinflammatory markers in the pathology of DR, including NF-κB, iNOS,
cyclooxygenases, VEGF, IL-1β, TNF-α, Fas, FasL, and complement factors
[23-39] - all of which contribute to an environment that is characteristic of
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chronic inflammation. However, roles of anti-inflammation and SPMs in DR
pathogenesis are still largely unknown. The studies described herein will
expand the traditional view of DR pathogenesis into the influence of type 1/type
2 dominant inflammatory responses and SPMs that will be examined using in
vivo and in vitro approaches, including C57BL/6J (B6) and BALB/cJ (BALB/c)
mice, residential retinal cell types (retinal endothelial cells and Müller cells) and
leukocytes (neutrophils/PMN) that are associated with DR pathogenesis.
The type 1 and type 2 immune response paradigm describes the
predominance of differentially programmed innate immune activities. Type
1/type 2 refers to the cytokine and chemokine expression from different kind of
cell types in local retinal inflammation instead of limiting to traditional polarized
CD4+ T helper cells. BALB/c (type 2 dominant) and B6 (type 1 dominant) strains
of mice have been demonstrated to be suitable models in experiments of
investigating type 1/type 2 immunity [40]. In type 1 responders, inflammatory
activity tends to be sustained and exacerbated, developing into chronic
inflammation, if left untreated. While in type 2 responders, the local
inflammation is less severe and resolves overtime [41]. Using a Pseudomonas
aeruginosa-induced bacterial keratisis model, previous work in our lab has
demonstrated benefits of type 2 dominant immune response in BALB/c mice in
terms of local homeostasis and reconsitution after infection [42, 43]. It has been
shown using a type 1 diabetic model that, type 1 cytokines are correlated with
desturction of pancreatic islets, while type 2 cytokines are thought to provide
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protection [44]. Hence, the current experiments will expand upon what is known
regarding inflammation in diabetes, the potential influence of a type 1 versus a
type 2 immune respsone and its featured cytokines in DR. It is expected that by
studying the anti-inflammatory response and role of SPMs in the diabetic
mouse model will reveal key intervention points for the treatment of early stage
diabetic retinopathy.
1.4 Retinal Endothelial Cells
REC line retinal capillaries and are responsible for maintaining homeostasis
of the blood-retinal barrier, with pericytes to structurally support them (Fig. 4).
To maintain the active retina, the retinal endothelium ensures the nutrient
requirements and oxygen supply. It also helps to isolate the retina from toxins,
microorganisms and pro-inflammatory leukocytes [45]. Therefore, the retinal
endothelium is one of the major components involved in retinal ischemic
pathology and retinal inflammation associated with DR, as they are the first line
of residential cells that directly interact with docked and infiltrating immune cells.
Studies have revealed that retinal capillary cells undergo accelerated apoptosis
before clinical signs of DR are apparent [46, 47]. During DR, the tight junctions
among REC are interrupted by high glucose-induced pressure resulting in
leaking retinal microvasculature [13]. In addition, REC play an essential role
during neovascularization upon ischemic stimulation, with elevated levels of the
angiogenic factor, VEGF, identified as a hallmark event [48]. In an experimental
autoimmune uveitis model, scanning laser ophthalmoscopy has demonstrated

- 13 -

Figure 4. Diagram of longitudinal section (A) and cross-section (B) of a retinal
blood vessel. Source: Mills et al., Cells, 2013.
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that leukocytes migrate through the retinal microvasculature [49]. During
inflammation, retinal endothelial cells respond to the extracellular molecules
secreted by these immune cells. But more importantly, REC contribute to the
inflammatory response by secreting cytokines themselves. The intraocular
levels of TNF-α and IL-1β have been shown to be upregulated in patients with
posterior ocular inflammation [50, 51]. Human REC produce TNF-α and IL-1β,
as well as IL-6, in response to the presence of extracellular cytokines [52, 53].
It also has been demonstrated that human REC are capable of
immunomodulation through IFNs and toll-like receptors (TLRs) [54]. In addition,
REC possess enzyme synthesis activity, such as matrix metalloproteinases
(MMPs) [52], of which MMP-2 and MMP-9 play important roles both in vivo and
in vitro [55, 56]. In the current research plan, due to the aforementioned
significance regarding pro-inflammatory, angiogenic and chemotactic roles of
REC, they will be used as one of the major cell types to study type 1/type 2
responses during the development of DR.
1.5 Müller Cells
Müller cells or Müller glia are one of three resident glial cell types in the
retina. Müller cells serve as the supporting cells for the neuronal retina. Müller
cells span the full retinal thickness with the somata located in the inner nuclear
layer (INL) (Fig. 5). From the somata arise two major trunks; the inner trunk
projects to other Müller cells and photoreceptors, while the outer trunk extends
into the vitreous [57]. This close anatomical relationship allows for an intimate
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Figure 5. Illustration representing the organization of the mature retina. Muller
glial cell is shown in blue. Source: Belecky-Adams et al., Neural Stem Cells – New
Perspectives, 2013.
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physiological regulation among Müller cells, neurons and blood vessels in the
retina [58, 59]. As a type of neural supporting cell in the retina, Müller cells
produce signaling proteins for neural survival, growth and differentiation, such
as brain derived neurotrophic factor (BDNF) [60, 61]. Clinical studies
concerning fibrovascular membranes have demonstrated high expression
levels of various pro-inflammatory cytokines by this cell type, including TNF-α,
VEGF and IL-6 [62, 63]. Moreover, stimulation of β-adrenergic receptors on
Müller cells leads to decreased levels of TNF-α, IL-1β, iNOS and proinflammatory lipid mediator PGE2 [64]. As TNF-α, IL-1β, NO and PGE2 are all
important inflammatory mediators upregulated under hyperglycemic conditions,
these results suggest the involvement of Müller cells during the pathogenesis
of DR. Müller cells are also associated with the mediation of extracellular matrix
deposition by producing MMP-2 and MMP-9, regulated with TNF-α [65].
However, it remains unclear how Müller cells are influenced under type 1 and
type 2 immune responses. In light of the aforementioned inflammatory and
angiogenic effects and its supporting network with REC, this resident retinal cell
type is another key player in the pathogenesis of DR.
1.6 Leukostasis and PMN
Neutrophils are the first leukocytes recruited to inflammatory sites and then
neutralize invading pathogens by phagocytosis, degranulation and the release
of neutrophil extracellular traps. [66] In terms of inflammation, PMN react to
different cytokines, growth factors and bacterial stimulation [67, 68], further
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expand their lifespan and drive resolution of inflammation by activating adaptive
immune responses in normal physiological condition. Diabetes results in
recruitment of inflammatory mediators into the retina. Studies have indicated
that neutrophils are significantly increased in retinal (and choroidal) vessels
from diabetic patients and other animal models. [69, 70]
The notion that inflammation is involved in the pathogenesis of DR is largely
supported by retinal leukostasis. Furthermore, the static infiltration of
leukocytes into the retinal vasculature is thought to play a significant role during
early DR and contributes to vascular leakage, increased permeability of the
blood-retina barrier and then ischemia followed by angiogenesis. As mentioned,
ICAM-1 and CD18 expressed by resident retinal cell types and infiltrating
inflammatory cells, such as neutrophils, were found to be significantly
upregulated in DR models, further supporting the leukostasis process during
DR [19-22].
1.7 Pro-Resolving Lipid Mediators
Over the last decade, research regarding SPMs has introduced a new
mechanism of inflammation that suppresses inflammation and promotes
resolution. Resolution of inflammation is an active process where the class
switch of pro-inflammatory prostaglandins to SPMs plays an important role in
resolution of inflammation [71]. Resolvins are a family of protective, proresolving compounds produced by docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA) biosynthetic pathways [72]. Resolvin D1 (RvD1)
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is converted by 15-lipoxygenase (LOX) and 5-LOX from D-series -3
polyunsaturated fatty acids and exert their function by binding to G proteincoupled receptors ALX/formyl peptide receptor 2 (FPR2) and G protein-coupled
receptor 32 (GPR32) [73]. Resolvin E1 (RvE1) has another G-protein coupled
receptor ChemR23, and is generated by acetylated COX-2 and 5-LOX. DHA
can also be converted into neuroprotectin/protectin D1 (NPD1/PD1) via
lipoxygenase activity. These PUFA-derived lipid mediators exert their antiinflammatory function by driving resolution of inflammation, organ protection
and anti-fibrotic activity, which contributes to their classification as “proresolving” lipid mediators or SPMs. As described, SPMs can be biosynthesized
by LOX enzymes, which comprise the main pathways for SPM biosynthesis. In
particular, 15-LOX is largely protective and is a key enzyme for the generation
of SPMs [74]. Detailed diagram of illustrated lipid mediator pathways are shown
in Figure 6.
It has been widely accepted that SPMs exert their anti-inflammatory and
resolving effect by limiting infiltration of inflammatory cells; RvD1 reduces PMN
infiltration and increases nonphlogistic phagocytosis of apoptotic PMN [75].
LXA4, first discovered to be pre-resolving, provides stop signals for PMN
infiltration thus limiting the intensity of inflammation [76]. PGD2, along with the
PGE2, can switch their pathway during acute inflammation and then generate
enzymes essential for the production of lipoxins in PMN [77]. RvE1 is another
important regulator of PMN chemotaxis and activation under inflammation in
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Figure 6. Synthetic pathways of pro-resolving lipid mediators. Source: Serhan,
C.N. et al., Discovery of specialized pro-resolving mediators marks the dawn of
resolution physiology and pharmacology. Mol Aspects Med, 2017. 58: p. 1-11
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vivo [78]. Endogenous PD1/NPD1 has been demonstrated to mediate PMN
infiltration, while other D-series resolvins can downregulate TNF-α and IL-1β,
limiting PMN transmigration and activation into inflammatory tissues [72, 79,
80]. Regarding DR, DHA-rich diet in fish oil was shown to decrease
complications in diabetic retinopathy by inhibiting retinal microvascular damage,
downregulating expression of pro-inflammatory molecules IL-1β, IL-6 and
ICAM-1 [81]. A protective effect of RvD1 against diabetic neovascularization
has been demonstrated, in part through the suppression of the proinflammatory cytokine TNF-α [82]. In addition, an intermediate metabolite of
DHA synthesis pathway, 4-HDHA reduced retinal neovascularization [83]. In the
current studies, we looked at the whether these pathways were involved in the
pathogenesis of DR.
1.8 NF-κB
NF-κB is composed of a family of transcription factors that regulates
transcription of broad range of genes to control physiological and
pathophysiological activities, such as inflammation and immune activity, cell
growth, apoptosis and cancer. It contains 5 subunits - p65 (RelA), RelB, p50,
p52 and c-Rel, which dimerize before nuclear translocation and trigger
transcription of target genes. Traditionally, the NF-κB pathway is activated by
IL-1 receptor (IL-1R), TNF receptor (TNFR) and TLRs, known to be the
canonical NF-κB pathway. Other relatively newly found activators include
lymphotoxins, CD40 ligand and B-cell activating factor, which activate the non-
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canonical NF-κB pathway [84]. In the canonical NF-κB pathway, IKKα, IKKβ and
IKKγ are activated, promoting phosphorylation, ubiquitination and degradation
of IκBα, which binds to the p65-p50 dimer, isolates it and inhibits its activity in
the cytosol. Upon release from IκBα, the p65-p50 dimer is phosphorylated and
translocated into the nucleus, then after recruiting transcription factors such as
p300/CBP and HDAC, binds to target genes and stimulates their transcription.
The p65-p50 dimer is well studied and described as the major contributor of
NF-κB activity [85]. On the other hand, IKKα itself was demonstrated to play
important role in the non-canonical NF-κB pathway, followed by the activation
and translocation of RelB-p52 dimer. For the interest in present studies,
differential phosphorylation of NF-κB p65 in high glucose, pro- versus antiinflammatory cytokines and its regulation on pathogenic inflammatory genes
are explored here.
In diabetes, NF-κB starts to play an important role from very early stages of
pathogenesis. In T1DM, NF-κB is activated by IL-1β and induces pancreatic
beta cells dysfunction and death [86]; in T2DM, NF-κB is constitutively activated
as a result of the low-grade, chronic inflammatory state [87]. NF-κB plays a
pivotal role in DR pathogenesis by responding to hyperglycemia/hypoxia
activated pathways and further activating more pathogenic cascades. First of
all, ROS is produced by residential cells and inflammatory cells during DR,
damage DNA and activates NF-κB [88]. AGEs, by activating RAGE receptors,
interacting with PKC pathway, both activate NF-κB [89, 90]. Next, NF-κB
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stimulates further transcription of inflammatory mediators that exacerbate DR
pathogenesis in multiple aspects (Fig. 7): 1) pro-inflammatory cytokines and
chemokines including IL-1β, TNF-α, interleukin-6 (IL-6), IL-8 and monocyte
chemotactic protein-1 (MCP-1) [91-95]; 2) inducible nitric oxide synthase (iNOS)
[96]; 3) cyclooxygenase-2 (COX-2) for the production of pro-inflammatory
prostaglandins [97]; 4) adhesion molecules ICAM-1 and VCAM-1 [98]; 5)
apoptotic molecules - Fas and Fas ligand (FasL) [99]. Additionally, NF-κB
pathway has long been known to play central role in not only directing
inflammation, but also in terms of reacting to metabolic pathogens [87]. For
example, IKK kinase was used for treatment target in T2DM [100], which
features low grade, chronic systemic inflammation. IKKβ activation is also
implicated in diabetes by regulating insulin signaling and insulin sensitivity [101].
1.9 Ischemia/Reperfusion
Ischemia/reperfusion (I/R) injury, also known as reperfusion injury, is a
tissue damaging process that is caused by reperfusion of the blood supply into
previously ischemic tissue. During this process, instead of recovering to normal
physiological conditions, restoration of the blood supply induces oxidative
stress, thus resulting in inflammation [102]. Cardiovascular system dysfunction,
stroke and thrombotic damage can take place at the beginning stage of
ischemia [103, 104], creating an aerobic local environment. The maximum time
length each tissue could survive from ischemic damage varies and can result
in necrosis [105], yet restoration of blood supply usually removes ischemic
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Figure 7. Pivotal regulatory role of NF-κB in pathogenesis of DR.
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damage and instead, promotes free radical-induced reperfusion damage [106].
It is hypothesized that absence of oxygen during the ischemic stage leads to
production of various intermediates, which are converted to tissue-damaging
free radicals during oxygen resupply [107, 108]. The oxygen radicals activate
different pathogenic cascades that evoke the inflammatory response.
Production of IL-8 and adhesion molecules promote docking and invasion of
inflammatory cells, most importantly neutrophils and macrophages. As a result,
local

inflammation

in

I/R

tissues

is

exacerbated,

causing

further

pathophysiological responses and tissue damage.
During DR, apoptosis of pericytes and REC, disruption of tight junctions,
and breakdown of the blood-retinal barrier results in microvascular leakage,
creating an ischemic condition [109]. This induces production of pathogenic
molecules such as oxygen radicals [110], hypoxia inducible factor-1 (HIF-1) [111]
and cytokines/chemokines. Earlier studies have demonstrated that retinal
ischemia/reperfusion leads to microvascular damage that is similar to what is
observed in DR and glaucoma [112]. Moreover, free radicals were also found
to promote neurodegeneration in retinal I/R [113]. Thus, I/R surgery is suitable
to mimic neurodegeneration, microvascular leakage and inflammation in DR,
which have been demonstrated in different studies [112, 114]. To this end, I/R
is used to mimic DR-like changes in a short time frame in order to investigate
our type 1/type 2 immune response paradigm.

- 25 -

CHAPTER 2 “VIP PROTECTS PRIMARY HUMAN RETINAL
MICROVASCULAR
ENDOTHELIAL
CELLS
AGAINST
HYPERGLYCEMIA-INDUCED
INCREASES
IN
TNF-α
AND
ENHANCES PRO-RESOLVING RVD1”
2.1 Abstract
The purpose of our study was to evaluate the therapeutic effect of VIP on
human retinal endothelial cells (HREC) under high glucose conditions. Diabetes
affects almost 250 million people worldwide. Over 40% of diabetics are
expected to develop diabetic retinopathy, which remains the leading cause of
visual impairment/blindness. Currently, treatment is limited to late stages of
retinopathy with no options available for early stages. To this end, the purpose
of the current study is to evaluate the therapeutic effect of vasoactive intestinal
peptide (VIP) on HREC under high glucose conditions. Primary HREC were
cultured in normal (5mM) or high (25mM) glucose medium +/- VIP treatment.
Protein levels of TNF-α, resolvin D1 (RvD1), formyl peptide receptor 2 (FPR2),
G protein-coupled receptor 32 (GPR32), VEGF, and VIP receptors, VPAC1 and
VPAC2 were measured. High glucose-induced changes in TNF-α and RvD1
were restored to control levels with VIP treatment. RvD1 receptors, ALX/FPR2
and GPR32, were partially rescued with VIP treatment. VPAC2 expression
appeared to be the major receptor involved in VIP signaling in HREC, as
VPAC1 receptor was not detected. In addition, VIP did not induce HREC
secretion of VEGF under high glucose conditions. Our results demonstrate that
VIP's therapeutic effect on HREC, occurs in part, through the balance between
the pro-inflammatory cytokine, TNF-α, and the pro-resolving mediator, RvD1.
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Although VPAC1 is considered the major VIP receptor, VPAC2 is
predominantly expressed on HREC under both normal and high glucose
conditions.
2.2 Introduction
Diabetic retinopathy (DR) continues as the leading cause of irreversible
blindness in the United States resulting in over 10,000 new cases annually [2].
With both type 1 and type 2 diabetics at risk, over 40% of all adult diabetic
patients are expected to develop this visually debilitating disease. Despite the
fact that diabetes is projected to reach epidemic levels by 2030, there remains
no available treatment for early stage DR, save for maintaining glycemic control.
Hallmark features of DR are of both vascular and neural natures, including
leukocyte adhesion to retinal vasculature, vascular occlusions, endothelial cell
damage and pericyte and photoreceptor loss with underlying degenerative and
inflammatory changes [115]. Inflammation has been linked to DR as early as
the 1960’s when it was found that diabetic patients, who were administered
salicylates for rheumatoid arthritis, demonstrated a lower incidence of
retinopathy [116]. However, only more recently has the inflammatory response
come to the forefront as a major contributing factor to the development and
progression of DR.
TNF-α is a well-characterized cytokine known to play a role in a wide
spectrum of biological activities, predominately pro-inflammatory in nature. It
has been reported that TNF-α levels are increased in retinas of both type 1 and
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type 2 diabetic rodents, as well as during the development of DR [37]. It has
been indicated as a major cytokine involved in driving leukocyte adhesion.
Furthermore, it has been shown that this molecule induces endothelial and
pericyte cell injury and apoptotic cell death [115]; key events in the progression
of DR.
In contrast, resolvins are a family of protective, pro-resolving compounds
produced by docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)
biosynthetic pathways [72]. RvD1 is derived from D-series -3 polyunsaturated
fatty acids and binds to G protein-coupled receptors ALX/FPR2 and GPR32 [73],
leading to reduced polymorphonuclear leukocytes (PMN) infiltration and
increased nonphlogistic phagocytosis of apoptotic PMN [75]. A protective effect
of RvD1 against diabetic neovascularization has been demonstrated, in part
through the suppression of the pro-inflammatory cytokine TNF-α [82].
VIP is an endogenous immunoregulatory neuropeptide synthesized by
neurons throughout the central and peripheral nervous systems, in addition to
immune cells [117]. Focusing on the retina, VIP immunoreactivity has been
detected in amacrine cells and other interneurons of the inner nuclear layer (INL)
and inner plexiform layer (IPL) [118, 119]. The immunoregulatory activities of
VIP are mediated predominately by two G protein-coupled receptors,
VPAC1/VIPR1 and VPAC2/VIPR2. VPAC1 is constitutively expressed in
lymphocytes, macrophages, dendritic cells, microglia, monocytes and mast
cells, whereas VPAC2 is thought to require activation [120]. VPAC1 serves as
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the major immunoregulatory receptor for VIP in various immune cells, while
VPAC2 is thought to play a role in immune homeostasis and tissue restoration
[121, 122].
Recent studies have reported decreased expression of VIP and both
VPAC1/VPAC2 receptors in the retina during early stage DR [121, 123].
Moreover, in diabetic macular edema, activation of the protective VIP/PACAP
pathway has been shown to prevent the breakdown of the outer blood retinal
barrier by mediating tight junction integrity [124]. However, the modulatory
mechanism and potential therapeutic effect of VIP during the development of
DR is largely unknown. The current study seeks to demonstrate a potential proresolving role for VIP during DR by preliminarily investigating its interaction with
TNF-α and RvD1 in HREC under high glucose conditions.
2.3 Materials and Methods
Retinal Endothelial Cell Culture
Primary HREC were acquired from Cell System Corporation (CSC, Kirkland,
WA). Cells were grown in M131 medium containing microvascular growth
supplements (MVGS; Invitrogen, Carlsbad, CA), 10 mg/mL gentamycin, and
0.25 mg/mL amphotericin B. All primary cells were used within six passages.
Prior to experimentation, cells were transferred for three days to high (25 mM)
or normal (5 mM) glucose medium (M131 medium supplemented with glucose)
with MVGS and antibiotics, then quiesced by removing MVGS for 24h. Cells
were exposed to VIP (10-9 M) for 4h [125-127], followed by rinsing with cold
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PBS and collection into lysis buffer containing protease and phosphatase
inhibitors. Cellular extracts were prepared by sonication, and total protein
concentration was determined for analyses as described below.
To evaluate whether VIP acts directly via VPAC2 and/or ALX/FPR2
regarding TNF-α levels, cells were treated with the VIP receptor antagonist, [Dp-Cl-Phe6,Leu17]-VIP (Leu) (VPAC antagonist; R&D Systems, Minneapolis, MN)
or a selective antagonist of ALX/FPR2 signaling, WRW4 (Tocris, Pittsburg, PA).
Cells cultured under normal and high glucose conditions were exposed to VIP
(10-9 M) in the presence of each antagonist (VPAC antagonist at 2M or WRW4
at 1M) for 4h, then processed for protein analyses as described above.
Previously, high osmolar conditions have been included as an additional
control to determine whether the observed in vitro effects were a result of high
glucose treatment or increased osmolarity of the treatment media [128]. Since
it has been established that no differences were observed between high
osmolarity and normal glucose, this control was omitted from the current study.
ELISA
Protein levels for TNF-α and RvD1 were determined using ELISA kits
(Thermo Fisher Scientific, Waltham, MA; Cayman Chemical, Ann Arbor, MI).
Cells were collected and processed as described above. All samples were
centrifuged at 5,000 × g for 5 min and an aliquot of each supernatant was
assayed in duplicate or triplicate per the manufacturer’s instruction. Equal
protein was loaded into all wells. The reported sensitivities of these assays
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are as follows: <2.0 pg/mL for TNF-α and 3.3 pg/mL for RvD1.
Western Blotting
Proteins were separated on 4–12% tris-glycine gels (Invitrogen, Carlsbad,
CA) and transferred to nitrocellulose membranes. After blocking membranes in
TBST (10 mM Tris-HCl buffer, pH 8.0, 150 mM NaCl, 0.1% Tween 20) and 5%
(w/v) BSA at r.t. for 60 min, membranes were incubated overnight at 4⁰C with
antigen-specific primary antibodies. The primary antibodies were used as
follows: GPR32, ALX/FPR2 and VEGF (Abcam, San Francisco, CA); VPAC1
and VPAC2 (Santa Cruz, Santa Cruz, CA). Blots were then incubated with
species-specific HRP-conjugated secondary antibodies for 2 h at r.t. Proteins
were visualized by incubation with a chemiluminescence substrate kit (Thermo
Fisher Scientific, Waltham, MA). Western blot images were collected (Azure
Biosystem C500, Dublin, CA) and target protein expression was quantified
(Image Studio Lite software) after normalizing to β-actin. One representative
blot is shown. Treatment groups were normalized to β-actin levels and then
compared to normal glucose, which was normalized to 1.0.
Statistical analysis
All assays were carried out at least twice from two independent experiments
and the data are presented as mean + SEM. Data were analyzed by the
Kruskal-Wallis test, followed by Dunn’s testing. P < 0.05 was considered to be
statistically significant.
2.4 Results
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VIP reduced levels of high glucose-induced TNF-α
Changes in TNF-α protein levels were assessed under high glucose
conditions and after VIP treatment, as shown in Figure 8. As expected, TNF-α
protein levels were significantly increased by HREC under high glucose
compared to normal glucose conditions (control). This effect was abrogated
with VIP treatment, whereby TNF-α levels were similar to controls. No
significant effect was observed with VIP treatment in cells cultured in normal
glucose.
Effect of VIP on pro-resolving mediators
Our previous research has demonstrated VIP’s therapeutic effect to be both
anti-inflammatory and pro-resolving [42, 127, 129, 130]. As such, we next
addressed a potential mechanism by which VIP might mediate these proresolving effects by looking at RvD1 and corresponding receptors, ALX/FPR2
and GPR32. As illustrated in Figure 9A, RvD1 protein levels were significantly
reduced in high glucose versus normal glucose conditions. However, levels
were increased with VIP treatment in high glucose. No notable changes were
observed in HREC after VIP treatment under normal conditions.
In addition, RvD1 receptors ALX/FPR2 and GPR32 were significantly downregulated (approximately 50% and 40%, respectively) after high glucose
exposure compared to normal glucose controls (Fig. 9B and 9C, respectively),
which is consistent with the changes observed in their ligand, RvD1. Further,
VIP treatment enhanced protein levels of both receptors, albeit only GPR32
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was significantly increased (28%) over high glucose only. ALX/FPR2 and
GPR32 levels after VIP treatment of normoglycemic cells remained comparable
to controls.
VIP receptor expression by HREC
As the two predominant receptors of VIP, levels of VPAC1 and VPAC2 were
evaluated in HREC. Although described as the major VIP receptor on most cell
types [120], VPAC1 was not detected in HREC in either normal or high glucose.
In contrast, VPAC2 was constitutively expressed under both high and normal
glucose conditions (Fig. 10). However, VPAC2 protein levels were significantly
reduced in high glucose versus normal glucose conditions, despite VIP
treatment.
VIP-induced effects are carried out by VPAC2 receptors
Despite that VPAC2 was predominantly expressed on HREC, we next
confirmed whether the VIP-induced changes in TNF-α levels were directly
mediated by this receptor. To do so, HREC were cultured under high glucose
conditions, then exposed to a receptor antagonist for either ALX/FPR2 (WRW4)
or VPAC2 (Leu) prior to VIP treatment. As shown in Figure 11, results indicate
that VIP-induced down-regulation of TNF-α was abrogated in the presence of
the VPAC antagonist, but not the ALX/FPR2 antagonist. In fact, TNF-α levels
from HREC cultured in HG+VIP+Leu were comparable to HG only and
significantly higher than NG, NG+VIP and HG+VIP. While the ALX/FPR2
antgonist, WRW4, did result in a slight increase in TNF-α levels compared to
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HG+VIP, the difference was not significant.
VEGF levels are not affected by VIP treatment
Considerable clinical effort has been put forth to inhibit VEGF, as it is well
known to cause retinal permeability and neovascularization in diabetes. As VIP
was previously reported to enhance growth factor production [130], we
investigated VEGF protein levels after VIP treatment under both normal and
high glucose conditions to evaluate this potential side effect. As depicted in
Figure 12, VIP treatment did not have any effect on VEGF levels under normal
glucose conditions. Remarkably, high glucose-induced VEGF levels, however,
were significantly reduced after VIP treatment.
2.5 Discussion
Studies have indicated TNF-α is an important mediator of the retinal
pathology observed under hyperglycemic conditions, including leukocyte
adherence in retinal blood vessels [131], retinal endothelial cell apoptosis [132],
pericyte loss and capillary degeneration [133, 134] and vascular permeability
and leukostasis [135]. It has been previously shown by Jiang et al. that TNF-α
levels are increased in HREC cultured under hyperglycemic conditions [132].
Therefore, as an initial step towards characterizing the retino-protective effects
of VIP during DR, we examined whether VIP can regulate levels of this potent
pro-inflammatory cytokine. As expected, high glucose significantly induced
TNF-α

expression in HREC, suggesting its involvement in the diabetic

inflammatory response. VIP abrogated this effect, thus returning TNF-α to
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control levels. This anti-inflammatory effect of VIP has been reported in other
diabetic systems; as VIP was shown to inhibit TNF-α

induced apoptosis in

acinar cells isolated from submandibular glands of non-obese diabetic mice
with salivary dysfunction through functional VPAC1 receptors coupled to the
protein kinase A signaling pathway [136]. The current study suggests that VIP,
as an alternate treatment against DR, may effectively ameliorate the initial proinflammatory cytokine release observed in vivo; however this effect appears to
be VPAC1-independent and associated with the pro-resolving molecule, RvD1.
The balance between TNF-α

and RvD1 appears to be an important factor

in disease pathogenesis. Previous research also indicates that TNF-α

can

suppress RvD1 expression [82]. Using a uveitis model, topical ocular
application of RvD1 was shown to reduce levels of TNF-α

resulting in

improved disease outcome [137]. Likewise, in a diabetic mouse model, RvD1
expression was enhanced with the reduction of TNF-α following entanercept
treatment, leading to a reduction of pathological retinal angiogenesis [82]. This
resolvin has been demonstrated to reduce angiogenesis and protect against
retinopathy [82]. Therefore, we next sought RvD1 as a potential mechanism by
which VIP might mediate its pro-resolving effects. To this end, the current study
showed that high glucose conditions decreased RvD1 levels in HREC. More
importantly, VIP treatment effectively up-regulated RvD1 production after high
glucose exposure similar to observed normal glucose levels. In addition, high
glucose-induced reduction of ALX/FPR2 and GPR32 was partially rescued after
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VIP treatment. Both of these RvD1 receptors are important in carrying out the
resolution of acute inflammation by mediating PMN recruitment [138], and
promoting D1-miRNA circuits [138]. These data support the idea that VIP’s proresolving effects are carried out, at least in part, via lipid mediator circuits.
Further, the inverse relationship between TNF-α and RvD1 enhance the
efficacy of VIP as a potential therapeutic.
Although VPAC1 is broadly expressed on different cell types, most notably
immune cells [120], and has received considerable attention for its antiinflammatory effects, it was not detected in HREC. VPAC1 has been detected
in rat brain microvascular endothelial cells [139], as well as transformed murine
endothelial cells derived from heart (H5V) [140], indicating that a lack of VPAC1
detection could be unique to retinal endothelial cells. In contrast, VPAC2
appeared to be constitutively expressed under normal glucose conditions, yet
decreased after exposure to high glucose. We have previously shown in a
bacterial keratitis model that VPAC2 is more strongly correlated with tissue
homeostasis and disease resolution [129]. Regarding diabetes, Ma et al. have
indicated that VPAC2 activation leads to improved glucose and lipid metabolism,
while increasing insulin sensitivity in db/db mice [141]. In the current study, we
demonstrate that VPAC2, not VPAC1, is expressed by HREC, thus suggesting
a potential mechanism by which VIP treatment could ameliorate disease
progression of DR. Although VIP treatment was not able to rescue high glucoseinduced down-regulation of VPAC2, it is possible that this receptor could be
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associated with RvD1 expression/activation. In this regard, VIP-induced
changes in TNF-α levels were abrogated by a VPAC antagonist. These findings
support the notion that the observed VIP-mediated effects regarding this proinflammatory mediator are carried out primarily both of this receptor pathway,
which will be further explored in future in vivo studies.
In light of our previous research highlighting VIP’s ability to enhance growth
factor expression during corneal wound healing and reconstitution of the
extracellular matrix [42], we next determined whether this neuropeptide
increases VEGF levels. VEGF has been implicated as a major causative factor
in diabetic macular edema, retinal neovascularization and related complications
[142]. Remarkably, HREC expression of VEGF was significantly downregulated
in high glucose with VIP treatment compared to high glucose only. Similar to
the cornea, which must remain clear for accurate visual processing, VIP
treatment does not appear to induce angiogenesis via VEGF expression. These
findings are essential in moving forward with investigating VIP as an alternative
therapy for DR.
Overall, the current study reports the expression of VPAC2, but not VPAC1,
on retinal endothelial cells. Additionally, it indicates a novel regulatory role for
VIP over RvD1 levels. Taken together, these findings provide rationale to further
explore the therapeutic potential of VIP in the development and progression of
DR. This neuropeptide not only reduced anti-inflammatory mediators, but is tied
to important lipid mediator circuits, as well. In addition, these data suggest that

- 37 -

VPAC2 (not VPAC1) and ALX/FPR2 are the major receptors involved in VIP
signaling in HREC.
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Figure 8. TNF-α protein levels as detected by ELISA. HREC were cultured under
normal glucose (NG, 5 mM) and high glucose (HG, 25 mM) conditions +/- VIP
treatment (10-9 M) for 4 hours. Data shown are representative of two independent
experiments in duplicate and are expressed as mean + SEM. *P < 0.05 vs NG, #P
< 0.05 vs HG.
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Figure 9. Protein levels of RvD1 and its receptors in HREC treated with VIP.
HREC were cultured under normal glucose (NG, 5 mM) and high glucose (HG, 25
mM) conditions +/- VIP treatment (10-9 M) for 4 hours. Protein levels of RvD1 (A)
were measured by ELISA and its receptors ALX/FPR2 (B) and GPR32 (C) were
detected by Western blot. Data shown are representative of two independent
experiments in duplicate and are expressed as mean + SEM. *P < 0.05 vs NG, #P
< 0.05 vs HG.
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Figure 10. VPAC2 receptor levels. HREC were cultured under normal glucose
(NG, 5 mM) and high glucose (HG, 25 mM) conditions +/- VIP treatment (10-9 M)
for 4 hours. Protein levels of VPAC2 were examined by Western blot. Data shown
are representative of two independent experiments in duplicate and are expressed
as mean + SEM. *P < 0.05 vs NG, #P < 0.05 vs HG.
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Figure 11. TNF-α protein levels as detected by ELISA. HREC were cultured
under normal glucose (NG, 5 mM) and high glucose (HG, 25 mM) conditions +/ALX/FPR2 antagonist (WRW4) or VPAC antagonist (Leu) +/- VIP treatment (10-9
M). Data shown are representative of two independent experiments in duplicate
and are expressed as mean + SEM. *P < 0.05 vs NG, #P < 0.05 vs HG.
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Figure 12. Protein levels of VEGF as detected by Western blot. HREC were
cultured under normal glucose (NG, 5 mM) and high glucose (HG, 25 mM)
conditions +/- VIP treatment (10-9 M) for 4 hours. Data shown are representative of
two independent experiments in duplicate and are expressed as mean + SEM. *P
< 0.05 vs NG, #P < 0.05 vs HG.
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CHAPTER 3 “A REGULATORY ROLE FOR β-ADRENERGIC
RECEPTORS REGARDING THE RESOLVIN D1 (RvD1) PATHWAY IN
THE DIABETIC RETINA”
3.1 Abstract
Diabetic retinopathy is a visually debilitating disease with limited treatment
options available. Compound 49b, a β-adrenergic receptor agonist, has been
demonstrated to effectively reduce disease pathogenesis associated with
diabetic retinopathy. While the exact mechanisms are not fully understood,
previous studies have determined that it reduces the pro-inflammatory cytokine,
TNF-α, and inhibits apoptosis of the retinal microvasculature. As inflammation
becomes more recognized in driving disease pathogenesis, so does the
regulation by pro-resolving pathways as therapeutic points of intervention. The
current study sought to explore whether Compound 49b had any influence on
pro-resolving pathways, thus contributing to improved disease outcome. Using
in vivo (animal model of type 1 diabetes) and in vitro (retinal endothelial cells,
Müller cells, neutrophils/PMN) techniques, it was determined that high glucose
lowers pro-resolving lipid mediator, resolvin D1 (RvD1) levels and differentially
alters required enzymes, 5-lipoxygenase (5-LOX), 15-LOX-1 and 15-LOX-2.
RvD1 receptors formyl peptide receptor 2 (ALX/FPR2) and G-protein coupled
receptor 32 (GPR32) were also downregulated in response to hyperglycemic
conditions. Moreover, it was observed that β-adrenergic receptor activation
restored high glucose-induced decreases in both enzyme activity and RvD1
levels observed in vivo and in vitro. The current study is the first to describe a
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regulatory role for β-adrenergic receptors on pro-resolving pathways.
3.2 Introduction
Roughly 10% of Americans were diagnosed with diabetes in 2012 (National
Diabetes Statistics Report, 2014). Given that nearly 60% of diabetic patients
will develop some complications related to diabetic retinopathy, generation of
novel therapies is of paramount importance. While it is clear that the retinal
response to high glucose is multifactorial, including oxidative stress, vascular
endothelial cell growth factor (VEGF), protein kinase C, inflammatory mediators,
endoplasmic reticulum stress, and epigenetic changes, therapies to prevent or
delay progression of diabetic retinopathy continue to elude scientists. It has
been previously reported that docosahexaenoic acid (DHA) is abundant in the
retina [143]. This omega-3 fatty acid has recently been linked to the activation
of a number of enzymes and proteins reported to be anti-inflammatory, as well
as protective to tissues [144, 145]. Among them includes resolvin D1 (RvD1), a
D-series resolvin [72, 146], which has been shown to display potent antiinflammatory activity and control the inflammation-resolution balance in host
defense. Hypoxia was one of the early signals found to stimulate the production
of pro-resolving mediators, such as RvD1 and RvE1, as demonstrated in
hypoxic endothelial cells [72]. Work in the oxygen-induced retinopathy (OIR)
model of proliferative retinopathy has suggested that RvD1 is protective within
the retina, which was correlated with reduced TNF-α levels [82]. Furthermore,
4-hydroxy-docosahexaenoic acid (4-HDHA), an intermediate metabolite of DHA
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through

5-lipoxygenase

(5-LOX)

activity,

also

reduced

retinal

neovascularization [83]. This response was subsequently blocked when 5-LOX
was eliminated [83].
In order to generate RvD1, DHA is metabolized by both 5- and 15-LOX [72]
[146], which selectively interacts with receptors ALX/FPR2 and GPR32 [147].
Using the streptozotocin model of type 1 diabetes, it was found that loss of 5LOX (a key lipid mediator enzyme) resulted in reduced vascular damage,
oxidative stress, and leukostasis [148]. Work in db/db mice has revealed that
local application of RvD1 accelerated wound closure and decreased apoptotic
cell accumulation [149]. Further studies using db/db mice revealed that RvD1
treatment was protective against development of type 2 diabetes [150].
Additionally, studies in HepG2 cells demonstrated that RvD1 attenuated
endoplasmic reticulum stress-induced apoptosis in a model of non-alcoholic
fatty liver disease [151]. Taken together, data from multiple tissues suggest that
the pathological markers associated with diabetes lead to a significant reduction
in resolvins, which may further contribute to exacerbated retinal damage.
We have previously reported that Compound 49b, a -adrenergic receptor
agonist, demonstrates both anti-apoptotic and anti-inflammatory properties in
the diabetic retina and in retinal cells under hyperglycemic conditions [152]. For
that reason, we questioned whether -adrenergic receptor signaling may
regulate lipoxygenase enzyme expression and resultant RvD1 production,
particularly in two resident retinal cell types, REC and Müller cells.
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Polymorphonuclear leukocytes (PMN) were examined as well, in light of
increased leukostasis and the mounting pathogenic role of inflammatory cells
during the development of diabetic retinopathy. There is little on the role of adrenergic receptor regulation of lipid mediators in the eye. In vitro studies have
demonstrated that protein kinase A (PKA) can phosphorylate 5-LOX in PMN
[153]. In contrast, work in human airway endothelial cells suggests that 15-LOX1 can decrease 2-adrenergic receptor phosphorylation, leading to decreased
cAMP levels [154]. Additionally, mouse models of Alzheimer’s disease have
shown that norepinephrine induces expression of formyl peptide receptor 2
(ALX/FPR2) [155], which is one of two known receptors for RvD1 [73, 156].
Thus, the potential regulatory role for -adrenergic receptor signaling on RvD1
or lipoxygenase enzymes in a diabetic retinopathy model remains unknown.
We have previously reported that Compound 49b can reduce TNF-, as
well as SOCS3, under hyperglycemic conditions [152, 157]. Therefore, we
hypothesized that diabetes or high glucose culturing conditions would decrease
enzymatic levels of 15-LOX and downstream production of RvD1, which could
be ameliorated by Compound 49b. Indeed, we found that high glucose and
diabetic conditions significantly decreased 15-LOX, as well as RvD1 levels. In
addition, lipoxygenase enzymes and RvD1 were increased following
Compound 49b treatment.
3.3 Experimental procedures
Animals
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All mouse experiments were approved by the Institutional Animal Care and Use
Committee at Wayne State University (Protocol# 11-08-14). C57BL/6J wildtype
mice were purchased from Charles River Laboratories. Mice were made
diabetic by injections of 60 mg/kg of streptozotocin dissolved in citrate buffer for
5 consecutive days. Control mice received citrate buffer only. Glucose
measurements were done weekly, with glucose levels >250 mg/dL considered
diabetic. At 2 months of diabetes, 10 control and 10 diabetic mice received
Compound 49b (4μL containing 1 mM) (formulated by Dr. Duane Miller,
University of Tennessee Health Science Center, Memphis TN, in collaboration
with Dr. Jena Steinle) topically onto each eye for 14 days. After 14 days of
Compound 49b treatment, all mice were sacrificed and analyzed as described
below.
Retinal endothelial cell culture
Primary human retinal microvascular endothelial cells (REC) were acquired
from Cell System Corporation (CSC, Kirkland, Washington). Cells were grown
in M131 medium containing microvascular growth supplements (Invitrogen), 10
g/mL gentamycin, and 0.25

g/mL amphotericin B. Prior to the experiment,

cells were transferred to high (25 mM) or normal (5 mM) glucose medium (M131
medium with added glucose), supplemented with MVGS and antibiotics for 3
days. Only primary cells within passage 6 were used. Cells were quiesced by
incubating in high or normal glucose medium without MVGS for 24 hr.
Compound 49b treatment was then added at 50 nM for 24 hours, as done
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previously [152].
Müller cell (rMC-1) culture
Müller cells (rMC-1; kindly provided by Dr. Vijay Sarthy at Northwestern
University) were thawed and cultured in DMEM medium under normal glucose
(5mM) conditions. Medium was supplemented with 10% FBS and antibiotics.
Once cells reached ~ 80% confluency, they were passed into dishes containing
either high (25 mM) or normal glucose medium. Once ready for experimentation,
cells were moved to the appropriate medium without FBS to induce serum
starvation for 18-24 hours. Compound 49b was then applied at 50 nM for 24
hours prior to cell collection.
PMN isolation
Peritoneal PMN from C57BL/6 mice were harvested as previously
described [158]. In brief, mice received an intraperitoneal (IP) injection (1.0 mL)
of a 9% casein solution (Difco, Detroit, MI) administered 27 hours prior to cell
harvest, followed by a second injection 24 hours later. Cells were collected by
peritoneal lavage 3 hours after the second injection, washed 3× (200 ×g, 10
min), and then isolated using a Percoll gradient (100,000 ×g, 20 min). Cell
viability (>95%) and purity (>90%) were determined. Cells were resuspended
in media (RPMI 1640 supplemented with 3% FCS and antibiotics) containing
either normal glucose (5 mM) or high glucose (25 mM) for 24 hours (37⁰C, 5%
CO2). Cells were then exposed to Compound 49b treatment (50 nM) for an
additional 24 hours, prior to harvest for protein analyses.
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Cell treatment
REC were selectively treated with either propranolol, a -adrenergic
receptor antagonist, or PKA siRNA (Dharmacon, Lafayette, CO). For
propranolol work, cells were cultured under normal and high glucose conditions,
and treated with propranolol (50 nM) 30 minutes prior to 49b treatment. To
block the PKA pathway, cells were similarly cultured and transfected with PKA
siRNA at a final concentration of 20 nM as previously described [64] using
GenMute siRNA transfection kit (SignaGen, Rockville, MD) followed by 49b
treatment.
Western blotting
After appropriate treatments and rinsing with cold phosphate-buffered
saline, REC, rMC-1 and PMN were collected in lysis buffer containing protease
and phosphatase inhibitors and scraped into tubes. Retinal extracts were
prepared by sonication. Equal amounts of protein from the cell or tissue extracts
were separated on pre-cast tris-glycine gels (Invitrogen, Carlsbad, CA), and
then blotted onto nitrocellulose membranes. After blocking in TBST (10mM TrisHCl buffer, pH 8.0, 150 mM NaCl, 0.1% Tween 20) and 5% (w/v) BSA,
membranes were treated with the following primary antibodies: 5-LOX, 15-LOX1, 15-LOX-2, ALX/FPR2, GPR32 (Abcam, San Francisco, CA) and

-actin

(Santa Cruz, Santa Cruz, CA), followed by incubation with appropriated
secondary antibodies (Fisher Scientific, Pittsburgh, PA) labeled with
horseradish peroxidase. Antigen-antibody complexes were detected using a
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chemilluminescent reagent kit (Thermo Scientific, Pittsburgh, PA). Western blot
images were collected on an Azure Biosystem C500 machine (Azure
Biosystems, Dublin, CA) and densitometric analysis was performed.
ELISA
RvD1 ELISA kits (Cayman Chemical, Ann Arbor, MI) were used to measure
RvD1 expression in REC, rMC-1, PMN and retinal lysates. Equal protein
concentrations were added to all wells. Assay protocol was performed
according to the manufacturer’s instructions. Cross reactivity of this assay for
RvD2 and RvE1 is 0.05% and <0.01%, respectively.
Statistics
All experiments were repeated in triplicate and data are presented as the
mean ± SEM. Non-parametric Kruskal-Wallis with Dunn’s post-hoc tests were
used for the cell culture data. One-way ANOVA with a Student Newman Keul’s
post-hoc test was done for animal studies using Prism 7.0 software. P<0.05
was considered significant. Representative blots are shown for all Western blot
analyses.
3.4 Results
Compound 49b significantly increases RvD1 levels and receptors
ALX/FPR2 and GPR32 in the diabetic retina.
Since DHA is highly abundant in the retina [143], we determined whether
RvD1 levels and associated receptors, ALX/FPR2 and GPR32 [73, 156] were
altered under diabetic conditions (Fig 13A-C). In 2-month diabetic mice, levels
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of RvD1 (A), ALX/FPR2 (B) and GPR32 (C) were significantly decreased. In
contrast, Compound 49b treatment significantly enhanced expression of all
three proteins when compared to untreated diabetic mice. These results
suggest that Compound 49b may be protective to the diabetic retina through
key pro-resolving pathways.
Compound 49b prevents high glucose-induced decrease in RvD1 and
associated receptors in REC.
To determine which cell types may contribute to the observed RvD1 profile
in the diabetic retina, REC in normal and high glucose were treated with
Compound 49b. Parallel to the diabetic retina, RvD1 levels were significantly
decreased in REC exposed to high glucose conditions (Fig 14A). RvD1
receptors ALX/FPR2 and GPR32 were similarly downregulated with high
glucose (Fig 14B and 14C, respectively). After treatment with Compound 49b,
RvD1, ALX/FPR2, and GPR32 levels were significantly upregulated in REC,
despite hyperglycemic conditions, to levels similarly observed with normal
glucose.
Compound 49b results in differential expression of lipoxygenase enzymes
in REC.
5-LOX, 15-LOX-1 and 15-LOX-2 enzymes were significantly increased in
REC cultured in high glucose (Fig 15A-C). When REC grown in high glucose
were treated with Compound 49b, 5-LOX enzyme expression returned to levels
observed in normal glucose (Fig 3A), with further enhanced expression of 15-
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LOX-1 and 15-LOX-2 (Fig 15B and 15C), suggesting that -adrenergic receptor
signaling may differentially regulate key lipid mediator enzymes in REC.
Compound 49b did not affect RvD1, ALX/FPR2 or GPR32 in Müller cells.
Since Müller cells are the primary residential inflammatory cell type in the
retina, we examined whether they respond likewise to high glucose via changes
in the D-series resolvin pathway. As illustrated in Fig 16, neither high glucose
nor Compound 49b altered RvD1 levels in Müller cells (A). Similar responses
were displayed regarding ALX/FPR2 and GPR32 when compared to REC and
whole retinal lysates – levels were decreased in Müller cells in response to high
glucose (Fig 16B and 16C). However, Compound 49b had no apparent effect.
Compound 49b exhibited limited effects on high glucose-induced changes
in lipoxygenase enzymes in Müller cells.
As shown in Fig 17, 5-LOX (A) was significantly upregulated, while 15-LOX1 enzyme (B) was downregulated in Müller cells grown in high glucose; no
differences were observed with 15-LOX-2 (C). Compound 49b effectively
reduced 5-LOX levels to those similar to control. However, unlike REC and the
diabetic retina, Compound 49b treatment had no effect on either 15-LOX
expression in Müller cells cultured in high glucose.
High glucose conditions decreased RvD1, ALX/FPR2 and GPR32 levels in
PMN.
To investigate a systemic immune cell type that may respond to retinal
damage, isolated murine PMN were exposed to normal and high glucose +/-
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Compound 49b treatment. Protein levels of RvD1, ALX/FPR2 and GPR32 were
detected in PMN (Fig 18A-C). Exposure to high glucose resulted in significant
downregulation of all three molecules. Compound 49b did not appear to affect
RvD1 or GPR32 – levels remained unchanged under both normal glucose and
high glucose conditions. However, hyperglycemia-induced decreases in
ALX/FPR2 were restored after Compound 49b treatment.
Compound 49b had limited effect on lipoxygenase levels in PMN in high
glucose.
High glucose conditions significantly reduced 15-LOX-1 levels in PMN, with
no effect observed with 5-LOX or 15-LOX-2 (Fig 19A-C). Following Compound
49b treatment, levels for all three enzymes high glucose remained unchanged.
These results suggest that systemic immune cells may respond differently to adrenergic receptor agents compared to residential retinal cells.
Compound 49b effects on RvD1 in REC are dependent on -adrenergic
receptor signaling.
Compound 49b activity is carried out through -adrenergic receptor
mediated increases in PKA activity [152]. To determine the specificity of
Compound 49b’s observed influence on the pro-resolving RvD1 pathway, REC
were exposed to propranolol, a non-specific -adrenergic receptor antagonist,
or PKA siRNA in the presence of high glucose and/or Compound 49b. As shown
in Fig 20A, propranolol abrogated the effects of Compound 49b and resulted in
RvD1 levels similar to those observed with high glucose alone. Similar effects
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were seen with PKA siRNA (Fig 20B), whereby RvD1 levels were significantly
reduced comparable to high glucose alone despite Compound 49b treatment,
thus further suggesting a -adrenergic receptor signaling pathway-dependent
effect.
3.5 Discussion
Work in the OIR model has suggested that lipid mediators may reduce
retinal neovascularization, with lipoxygenase enzymes expressed primarily by
circulating cells [83]. Additionally, it has been demonstrated that RvD1 and
RvE1, as well as neuroprotectin, are protective in the OIR model, potentially
through reduced TNF- levels [82]. It is well established that early diabetic
retinopathy following streptozotocin (STZ) injections leads to increased TNF-α
levels [8, 115, 152]. Work in diabetic-induced 5-LOX knockout mice
demonstrated that loss of this key enzyme resulted in reduced degenerate
capillaries, leukostasis, and NF-κB levels, while reduced leukostasis only was
observed in diabetic 12/15-LOX knockout mice [148]. Furthermore, work in
humans has suggested that patients with diabetic retinopathy or diabetic
macular edema have decreased levels of resolvins and protectins [159]. Thus,
it appears that diabetes (both proliferative and non-proliferative) may alter
lipoxygenase levels, as well as resolvin activity. However, the regulation and
cellular source of these enzymes and resolving pathways is less clear.
Regarding the former, there are limited and conflicting data regarding the
potential regulatory role for β-adrenergic receptor signaling in relation to RvD1
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or lipoxygenase enzymes [153-155]. Based upon these studies, it is likely that
different cell types and/or systems could potentially activate different signal
transduction pathways for resolvin production specific to each system. Hence,
the current study sought to define potential regulatory pathways associated with
RvD1 expression in the diabetic retina and begin to identify the cellular source(s)
related to these pathways.
Compound 49b is a -adrenergic receptor agonist based structurally on
isoproterenol with chemical modifications to increase its ocular potency for use
as a topical treatment [152]. It has been previously shown to significantly reduce
cleaved caspase 3 in the diabetic retina and retinal endothelial cells [152, 160].
Moreover, we have demonstrated that hyperglycemia-induced increases in
TNF-α in REC and Müller cells [157, 161] can be effectively reduced by
Compound 49b [157, 161]. It has also been found that the protective effect of
RvD1 against diabetic retinopathy occurs in part through the suppression of
TNF-α [82]. Therefore, we determined whether Compound 49b could regulate
lipoxygenase enzymes and resultant RvD1 expression, ultimately contributing
to the reduction in TNF-α both in vitro (REC and Müller cell culture) and in vivo
(STZ-induced diabetic retina). We also examined PMN to extend our findings
to circulating inflammatory cells, given the role of leukostasis during
development and progression of diabetic retinopathy. Overall, our data indicate
that high glucose significantly reduces RvD1 and corresponding receptor levels
in the diabetic retina. Our findings in the STZ-induced diabetic mouse retina are
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in contrast to findings in the OIR model, where RvD1 levels were not altered
[83]. The observed differences in RvD1 could be due to glucose-induced
damage versus oxygen-induced damage. However, ALX/FPR2 and GPR32
(RvD1 receptors) were also decreased in the diabetic retina. In addition, similar
results were consistently observed for these same molecules tested in REC
after exposure to high glucose conditions. Correspondingly, treatment with
Compound 49b significantly increased RvD1 expression similar to normal
glucose both in the diabetic retina and in vitro using REC accompanied by
decreased 5-lipoxygenase and increased 15-lipoxygenase enzyme levels.
Upon further examination of retinal Müller cells, a slightly different response
was observed. While high glucose resulted in increased 5-LOX and decreased
15-LOX, ALX/FPR2 and GPR32 levels, RvD1 remained unchanged. This
suggests that Müller cells have a different profile in response to high glucose
than the whole retina or REC, with no change in RvD1 levels, but
downregulated receptor expression. Similar to REC and diabetic retina;
however, Compound 49b significantly reduced 5-LOX enzyme levels in Müller
cells cultured in high glucose, as well as increased ALX/FPR2 levels,
suggesting a potential regulatory pathway in Müller cells, albeit much less
responsive. Compound 49b did not affect GPR32 levels, indicating that RvD1
would most likely signal through ALX/FPR2 in Müller cells and warrants further
investigation. In the diabetic retina, REC and Müller cells, -adrenergic receptor
signaling appears to be pro-resolving, at least in part, through actions carried

- 57 -

out by RvD1 and ALX/FPR2. However, this needs to be further confirmed using
ALX/FPR2 antagonists and/or silencing of the PI3K/Akt signaling pathway to
determine the extent of RvD1/ALX/FPR2 in mediating the protective effects of
Compound 49b. Further, given the increased 5-LOX enzyme levels, it does not
rule out the potential role Müller cells may have in producing 5-lipoxygenasedriven pro-inflammatory lipid mediators, such as leukotrienes.
When we expanded our work to circulating inflammatory cells (namely PMN)
that are known to enter the retina during leukostasis, yet a different paradigm
appeared. Effects of high glucose culturing conditions resulted in decreased
RvD1, ALX/FPR2 and GPR32 levels; though were limited to decreased 15LOX-1 regarding lipoxygenase enzymes. Despite no response of 15-LOX-2 to
high glucose exposure, these results are not surprising given that 15-LOX-1 is
highly expressed by circulating leukocytes compared to 15-LOX-2, which is
thought to be more restricted to tissue expression. And though 5-LOX (and 15LOX-2) remain unchanged under high glucose conditions, these results
suggest that 15-LOX-1 may be the limiting enzyme in the production of RvD1
within the PMN. Furthermore, while RvD1, 15-LOX-1, ALX/FPR2 and GPR32
were significantly decreased in high glucose, only ALX/FPR2 was restored
toward normal glucose levels after Compound 49b treatment. Albeit a limited
receptor effect, it may have significant implications as RvD1 has been shown
to potently regulate both human and mouse neutrophils [4] [146].
These results suggest that although retinal cells appear to lose pro-
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resolving and lipoxygenase enzyme responses in high glucose, restoration
through stimulation of -adrenergic receptor signaling pathways may occur. As
such, we next confirmed that the observed effects of Compound 49b in RECs
were carried out through activation of -adrenergic receptor signaling, as
indicated using propranolol – a non-specific -adrenergic receptor antagonist.
In addition, this specificity was further confirmed using PKA siRNA to silence
the downstream -adrenergic receptor signaling pathway, as both approaches
resulted in blunted RvD1 expression under high glucose conditions despite
Compound 49b treatment. In contrast, while circulating PMN are partially
responsive to high glucose, they did not appear to be influenced by the adrenergic receptor agonist. This raises two points as to why PMN alone are
only partially responsive to high glucose compared to the response of retinal
cells. One potential explanation for the limited response to high glucose may
be related to the stimuli. PMN are designed to circulate throughout the body
and respond to specific damage. The 25mM glucose used in this study may not
be an appropriate damage stimulus for PMN. Likewise, it is possible that other
pro-inflammatory signals released from retinal cells or cell-cell contact with REC
may be required to elicit a more robust response from neutrophils. To this end,
the microenvironment of the retinal vasculature may allow for interplay between
REC and PMN that can be influenced by both high glucose conditions and
Compound 49b treatment.
Another key question arising from this study is why -adrenergic receptors
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may regulate RvD1? In the retina, it is clear that maintenance of -adrenergic
receptor signaling reduces inflammatory pathways [152, 162-164]. Although it
has been reported in activated microglia that isoproterenol (from which
Compound 49b is derived) increases (as opposed to decreases) levels of
inflammatory cytokines [165] [166], studies were carried out in chronic stress
and surgical trauma models – not models of high glucose or hyperglycemia. To
this end, we have shown a different effect of 49b on REC and Müller cells.
Compound 49b works through β1-adrenergic receptors in REC and β2adrenergic receptors. In both cases of these cell types, Compound 49b reduces
TNF-α [152, 167]. Once we established the actions on TNF-α, we then moved
to show its actions on TLR4. From these findings, we hypothesized it may work
on pro-resolving pathways, as well. To date, little to no information exists on adrenergic receptors and RvD1. Our findings that Compound 49b can increase
RvD1 in diabetic whole retina and REC grown in high glucose strongly indicate
that this may occur through -adrenergic actions on cAMP. Work in rat brain
astrocytes demonstrated that DHA release can be regulated by calciumindependent phospholipase A2 (iPLA2) [168]. DHA release was amplified by
PKA agonist application [168]. Since we have shown that Compound 49b
significantly increases PKA [152], it is possible that our findings on lipoxygenase
enzymes and RvD1 may relate to actions on PKA and iPLA2. These will be the
focus of further study.
Collectively, these data indicate for the first time a regulatory role for β-
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adrenergic receptors regarding pro-resolving pathways in the diabetic retina.
Activation of β-adrenergic receptor signaling pathway via Compound 49b
rescued hyperglycemic-induced decreases in RvD1, its key enzymes 5- and
15-LOX, as well as receptors ALX/FPR2 and GPR32 in the diabetic retina and
REC. Future insight into how β-adrenergic receptor signaling pathways
influence pro-resolving mediators in the diabetic retina may contribute to the
development of therapeutic modalities targeted at the resolution of inflammation,
not simply anti-inflammatory in nature.
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Figure 13. Compound 49b significantly increased RvD1 (A), ALX/FPR2 (B)
and GPR32 (C) in the diabetic retina. Data from whole retinal lysates from
C57BL/6 mice untreated (Ctrl+PBS), control mice treated with Compound 49b
(Ctrl+49b), streptozotocin-induced diabetic mice (STZ+PBS), or diabetic mice
treated with Compound 49b (STZ+49b). *P<0.05 vs. ctrl+PBS, #P<0.05 vs.
STZ+PBS. N=5 mice in each group.
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Figure 14. Compound 49b increased levels of RvD1 (A), ALX/FPR2 (B) and
GPR32 (C) in REC exposed to high glucose. REC cells were grown in normal
glucose (NG), normal glucose+Compound 49b (NG+49b), high glucose (HG) or
high glucose treated with Compound 49b (HG+49b). *P<0.05 vs. NG, #P<0.05 vs.
HG. N=4 for each treatment.
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Figure 15. Lipoxygenase enzymes were differentially expressed in REC cells
grown in high glucose and after Compound 49b treatment. 5-LOX (A), 15-LOX1 (B) and 15-LOX-2 (C) in REC cells grown in normal glucose (NG), normal
glucose+Compound 49b (NG+49b), high glucose (HG) or high glucose treated with
Compound 49b (HG+49b). *P<0.05 vs. NG, #P<0.05 vs. HG. N=4 for each
treatment.
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Figure 16. Müller cells grown in high glucose did not increase RvD1 levels
after Compound 49b treatment. Müller cells were grown in in normal glucose
(NG), normal glucose+Compound 49b (NG+49b), high glucose (HG) or high
glucose treated with Compound 49b (HG+49b). Panel A shows RvD1 protein
expression, panels B and C show Western blot results for ALX/FPR2, and GPR32
levels in Müller cells. *P<0.05 vs. NG, #P<0.05 vs. HG. N=4 for each treatment.
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Figure 17. Compound 49b displayed limited effects on 5-LOX in Müller cells
in high glucose. Müller cells were grown in in normal glucose (NG), normal
glucose+Compound 49b (NG+49b), high glucose (HG) or high glucose treated with
Compound 49b (HG+49b). Panels A – C illustrate Western blots for 5-LOX, 15-LOX1 and 15-LOX-2, respectively. *P<0.05 vs. NG, #P<0.05 vs. HG. N=4 for each
treatment.
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Figure 18. Compound 49b significantly increased ALX/FPR2 levels, with no
influence on RvD1 or GPR32 levels. RvD1 (A), ALX/FPR2 (B) and GPR32 (C)
expression in PMN exposed to normal glucose (NG), normal glucose+Compound
49b (NG+49b), high glucose (HG) or high glucose treated with Compound 49b
(HG+49b). *P<0.05 vs. NG, #P<0.05 vs. HG. N=4 for each treatment.
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Figure 19. Compound 49b had no effect on lipoxygenase levels in PMN
exposed to high glucose. Mouse PMN cells were exposed to normal glucose
(NG), normal glucose+Compound 49b (NG+49b), high glucose (HG) or high
glucose treated with Compound 49b (HG+49b). Western blots results are shown
for 5-LOX (A), 15-LOX-1 (B) and 15-LOX-2 (C) expression. *P<0.05 vs. NG,
#
P<0.05 vs. HG. N=4 for each treatment.
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Figure 20. Increased RvD1 levels after Compound 49b treatment in REC were
β-adrenergic receptor pathway specific. REC were exposed to normal glucose
(NG), normal glucose+Compound 49b (NG+49b), normal glucose+Compound
49b+propranolol or PKA siRNA(NG+49b+propranolol/siPKA), high glucose (HG),
high glucose treated with Compound 49b (HG+49b) and high glucose+Compound
49b+propranolol/PKA siRNA (HG+49b+propranolol/siPKA). ELISA results are
shown for RvD1 levels after treatment with propranolol (A) and PKA siRNA (B).
*P<0.05 vs. NG, #P<0.05 vs. HG. N=4 for each treatment.
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CHAPTER
4
“CHARACTERIZATION
OF
SITE
SPECIFIC
PHOSPHORYLATION OF NF-κB P65 IN RETINAL CELLS IN
RESPONSE TO HIGH GLUCOSE AND CYTOKINE POLARIZATION”
4.1 Abstract
Background
Inflammation is an important contributor to the pathogenesis of DR, a
severe blinding eye disease affecting nearly 60% of diabetic patients. NF-κB is
a master transcriptional regulator for a wide spectrum of inflammatory genes.
Although NF-κB is comprised of multiple subunits, p65 has received the most
attention. However, the p65 subunit can be phosphorylated at numerous sites,
for which the effects of DR-related conditions are not well characterized. Since
dysregulation of NF-κB has been linked to chronic inflammation, the current
study examines site specific p65 phosphorylation in retinal cells exposed to high
glucose and investigates the effects of cytokine polarization in the regulation of
the high glucose-induced inflammatory response.
Methods
Phosphorylation of NF-κB p65 was examined in human primary retinal
endothelial cells (HREC) and MIO-M1 Müller cells after exposure to high
glucose and pro- or anti-inflammatory cytokines. Cells were incubated in high
(25 mM) or normal (5 mM) glucose, then treated with IL-1β, TNF-α or IL-4. Cells
were then harvested at different time points to assess phosphorylation levels at
multiple p65 sites, including Thr-254, Ser-276, Ser-281, Ser-311, Ser-468, Ser529, Ser-536 and Thr-435. Related downstream gene activation was selectively
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measured by real-time RT-PCR, ELISA and/or Western blot.
Results
High glucose exposure resulted in differential phosphorylation of p65
subunit sites between HREC and Müller cells. Pro-inflammatory cytokines
further exacerbated the phosphorylation of these sites while influencing
additional sites that were not altered in high glucose. In contrast, IL-4 exhibited
a generally suppressive effect on the phosphorylation of p65 sites in both HREC
and Müller cells, and promoted expression of IκBα. Downstream inflammatory
mediators were more activated in response to pro-inflammatory cytokine
treatment than high glucose exposure. Anti-inflammatory IL-4 inhibited
expression of downstream NF-κB regulated inflammatory genes, while IL-10
levels were significantly enhanced even in the presence of high glucose.
Conclusion
The current study is the first to characterize high glucose-induced NF-κB
p65 phosphorylation after cytokine polarization. By understanding NF-κB
phosphorylation and cytokine influence during hyperglycemic conditions,
intervention points can be identified for early stage treatment of DR.
Keywords: diabetic retinopathy, NF-κB, p65, phosphorylation, interleukin-4,
inflammation
4.2 Background
Diabetes mellitus (DM) is a chronic, metabolic disease resulting in high
blood glucose levels in the body. Diabetic retinopathy (DR) is a visually
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debilitating eye complication of diabetes that is the leading cause of blindness
among working age patients in the United States [2]. This disease exhibits
several pathological events associated with the retina. The early stage of DR,
with its featured complications of microaneurysms, hard exudates and
progressing hemorrhages, continues to lack effective treatments [169].
Although intensive efforts have been put into understanding pathogenic
mechanisms of DR, remarkable intervention points for treatment against nonproliferative stages of DR have yet to be found. Current anti-vascular
endothelial growth factor (VEGF) treatments risk deleterious side effects such
as endophthalmitis, intraocular inflammation and elevated intraocular pressure
[7], with compromised efficacy around 50% and requires repetitive
administration [170].
Inflammation was found to be associated with diabetes back in 1960s [18];
since then, leukostasis and associated local inflammatory activities have been
demonstrated to be key contributors for retinal non-perfusion, retinal ischemia
and resultant retinal vascular leakage during DR [19-22]. The retinal
endothelium is part of the blood-retinal barrier which isolates the retina from
toxins, microorganisms and pro-inflammatory leukocytes [45]. Retinal
endothelial cells (REC) line the microvasculature with surrounding pericytes
[171]. They are directly exposed to hyperglycemic conditions and interact with
infiltrating leukocytes. During inflammation, RECs respond to extracellular
molecules secreted by both residential retinal cells as well as immune cells.
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While DR was traditionally characterized as a microvascular disease, it is now
being viewed as a neural degenerative disease [116], as well. Müller cells are
supporting glia in the retina and one of the earliest residential cellular
responders during the pathogenesis of DR [172]. They actively react to
inflammatory cytokines and secret various molecules to modulate the
microenvironment during the development of DR, including RECs [173].
Additionally, it has been demonstrated that reactive oxygen species (ROS)
toxicity in RECs was derived from retinal Müller cells and pigment epithelial
cells through paracrine effects rather than a direct effect of high glucose [174],
suggesting a role for this cell type during the development of this disease.
NF-κB is a major transcription factor evoked by a number of stimuli,
including pro-inflammatory cytokines. Activation of NF-κB further enhances the
inflammatory response by inducing the transcription of wide spectrum of
inflammatory mediators related to leukocyte recruitment and cytokine
production [85]. Five NF-κB subunits have been well characterized and
associated with its activity, including RelA (p65), RelB, p50, p52 and c-rel [175].
Under normal conditions, NF-κB is sequestered within the cytoplasm through
the direct interaction with inhibitor proteins such as IκBα. Upon activation, the
IKK complex phosphorylates IκBα. Further ubiquitination and degradation of
IκBα releases the transcription activating subunits of NF-κB [175]. The classic
pathway of NF-κB activation is triggered by IL-1 receptor (IL-1R), TNF receptor
(TNFR) and pattern recognition receptors (PRRs), through downstream
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activation of IKKβ, IκBα and release of p65-p50 [175]. In contrast, the noncanonical NF-κB pathway is activated by CD40 ligand, lymphotoxin-β and
depends on activation of IKK

and release of p52-RelB [175]. When released,

p65-p50 and RelB-p52 heterodimers translocate into the nucleus, recruiting
transcription co-activators such as cAMP-response element binding protein
(CREB) binding protein (CBP)/p300 and histone acetyltransferase (HATs), and
activate transcription of downstream molecules by binding to target DNA
elements [175].
Site-specific phosphorylation of NF-κB p65 subunit leads to the selective
transcription of downstream pro-inflammatory genes [176]. As the best
characterized subunit of NF-κB, p65 and its phosphorylation is a pivotal point
for canonical NF-κB activation. However, multiple phosphorylation sites have
been mapped in both the N-terimal Rel homology domain and C-terminal
transactivation domain of p65; Ser-205, Thr-254, Ser-276, Ser-281 and Ser-311
are located in N-terminal Rel homology domain, while Thr-435, Ser-468, Thr505, Ser-529, Ser-535, Ser-536 and Ser-547 are found in C-terminal
transactivation domain [176]. It has been shown that during inflammation,
phosphorylation of Ser-276, Ser-281, Ser-311, Ser-468, Ser-529, Ser-536 and
Thr-435 stimulate transcriptional activity, while Thr-254 is involved in
stabilization and nuclear translocation [84]. Since the high glucose-induced
influence on different NF-κB p65 phosphorylation sites is unknown, we first
sought to characterize these sites in RECs and Müller cells under such
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conditions.
Inflammation is a protective immunomodulatory response, during which
pro-inflammatory mediators are counterbalanced by anti-inflammatory agents.
During DR, pro-inflammatory cytokines, mainly interleukin-1 beta (IL-1β) and
tumor necrosis factor-alpha (TNF-α) are produced by residential retinal cells,
neutrophils and macrophages and shape the inflammatory response that
contributes to disease pathogenesis [23, 33]. Both of these inflammatory
mediators are canonical NF-κB pathway activators. In type 1 diabetes, IL-1β
activates NF-κB and induces pancreatic beta cell dysfunction and death [86],
while in type 2 diabetes NF-κB is constitutively activated by a low-grade, chronic
state of inflammation [87]. Regarding DR, NF-κB has been shown to be
activated early and remain activated for up to 14 months in experimental animal
models and cultured retinal cells [23]. In contrast, interleukin-4 (IL-4) is
associated with anti-inflammatory immune responses and influences further
differentiation of T cells into Th2 cells. It has potent anti-inflammatory effects on
other leukocytes such as polymorphonuclear leukocytes (PMN) and monocytes
[177]. It has been reported that IL-4 inhibits insulitis and diabetic mellitus by
stimulating a Th2 response [178]. In terms of DR, clinical studies have indicated
significantly elevated levels of IL-4 in both vitreous and aqueous humor in
patients, together with other pro-inflammatory cytokines [179, 180]. However,
little is known on the anti-inflammatory effect of IL-4 in DR. In addition, whether
IL-4 has any regulatory effect on NF-κB phosphorylation has yet to be found.
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As such, we sought to investigate the effects of cytokine polarization in human
primary retinal endothelial cells (HREC) and Müller cells exposed to high
glucose in regulating NF-κB p65 site specific differential phosphorylation and
downstream inflammatory mediators.
4.3 Methods
Cell Culture & Cytokine Time Course Treatment
Primary HRECs (Cell System Corporation; Kirkland, WA) were grown in
HREC medium containing microvascular growth supplements (MVGS;
Invitrogen, Carlsbad, CA), 10 mg/mL gentamycin, and 0.25 mg/mL
amphotericin B. All cells were used within six passages. The MIO-M1 Müller
cell line was obtained from the UCL Institute of Ophthalmology, London UK.
MIO-M1 Müller cells were cultured in Dulbecco’s modified eagle medium
(DMEM) with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA), 10
mg/mL gentamycin, and 0.25 mg/mL amphotericin B. Prior to experimentation,
cells were transferred for four days to high (25 mM) or normal (5 mM) glucose
medium (HREC medium or DMEM medium supplemented with glucose) with
MVGS or FBS and antibiotics. Cells were then quiesced by removing MVGS or
FBS for 24h. Cells were treated with pro-inflammatory cytokines IL-1β (10
ng/mL, R&D Systems, Minneapolis, MN) or TNF-α (10 ng/mL, R&D Systems,
Minneapolis, MN) versus anti-inflammatory cytokine IL-4 (20 ng/mL, R&D
Systems, Minneapolis, MN) for 10 min (MIO-M1 only), 30 min, 2 h, 24h, followed
by rinsing with cold PBS. Since Müller cells are early responders in DR and
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have similar characteristics with macrophages [181], an earlier time point of 10
minutes was added for the analysis of these cells. Cell collection was carried
out as detailed below.
Western Blotting
Cells were collected in lysis buffer containing protease and phosphatase
inhibitors for protein isolation. Cellular extracts were then prepared by
sonication, and total protein concentration was determined for Western blot
analyses. Proteins were separated on 4–20% tris-glycine gels (Invitrogen,
Carlsbad, CA) and transferred to nitrocellulose membranes. After blocking
membranes in TBST (10 mM Tris-HCl buffer, pH 8.0, 150 mM NaCl, 0.1%
Tween 20) and 5% (w/v) BSA at r.t. for 60 min, membranes were incubated
overnight at 4°C with antigen-specific primary antibodies. The primary
antibodies were used as follows: anti-NF-κB p65 (phospho Thr-254), anti-NFκB p65 (phospho Ser-276), anti-NF-κB p65 (phospho Ser-281), anti-NF-κB p65
(phosphor Ser-311), anti-NF-κB p65 (phospho Ser-468), anti-NF-κB p65
(phospho Ser-529), anti-NF-κB p65 (phospho Thr-435), anti-IκBα (Abcam, San
Francisco, CA); Anti-NF-κB p65 (phospho Ser-536), anti-vascular cell adhesion
protein 1 (VCAM-1) (Cell Signaling Technology, Danvers, MA); anti-COX-2,
anti-β-actin (Santa Cruz, Santa Cruz, CA). Blots were then incubated with
species-specific HRP-conjugated secondary antibodies for 2h at r.t. Proteins
were visualized by incubation with a chemiluminescence substrate kit (Thermo
Fisher Scientific, Waltham, MA). Western blot images were collected (Azure
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Biosystem C500, Dublin, CA) and target protein expression was quantified
(Image Studio Lite software) after normalizing to β-actin. One representative
blot is shown.
Real-time RT-PCR
RNA was extracted by RNA STAT-60 (Tel-Test, Friendswood, TX, USA) per
the manufacturer’s protocol and subjected to real-time RT-PCR analyses. Total
RNA extracted for HREC and MIO-M1 was quantitated by spectrophotometric
determination (260 nm). Total RNA (100 ng) was reverse transcribed and used
to produce a cDNA template as previously described [182]. cDNA products
were diluted 1:20 with DEPC-treated water, and 2 μL cDNA (10-μL total reaction
volume) was used for semi-quantitative real-time RT-RT-PCR analysis (CFX
Connect Real-Time RT-RT-PCR Detection System; BioRad, Hercules, CA,
USA). All human primer pair sequences designed in the laboratory
(PrimerQuest, Integrated DNA Technologies, Coralville, IA, USA) are listed in
Table 1. RT-PCR amplification conditions were determined using routine
methods [183]. Relative transcript levels were calculated using the relative
standard curve method comparing the amount of target normalized to an
endogenous reference, β-actin. Data are shown as the mean ± SD for relative
transcript levels and represent at least two individual experiments.
ELISA
Intercellular adhesion molecule-1 (ICAM-1), interleukin-8 (IL-8), interleukin10 (IL-10) (R&D Systems, Minneapolis, MN), IL-1β and TNF-α(Thermo Fisher
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Table 1. Primer sequences.
Genes

Definition

Forward (5’ to 3’)

Reverse (5’ to 3’)

ICAM-1

Intercellular

CTTCGTGTCCTGTATGGCCC

CACATTGGAGTCTGCTGGGA

GTCAATGTTGCCCCCAGAGATA

ACAGGATTTTCGGAGCAGGA

adhesion molecule
1
VCAM-1

Vascular

cell

adhesion protein 1
IL-1β

Interleukin 1 beta

AGAAGTACCTGAGCTCGCCA

CTGGAAGGAGCACTTCATCTGT

IL-6

Interleukin 6

TACAGGGAGAGGGAGCGATA

CTCAGACATCTCCAGTCCTCT

IL-8

Interleukin 8

AGAGCCAGGAAGAAACCACC

GGCAAAACTGCACCTTCACAC

IL-10

Interleukin 10

AAGACCCAGACATCAAGGCG

AATCGATGACAGCGCCGTAG

TNF-α

Tumor

AGGCGCTCCCCAAGAAGACA

TCCTTGGCAAAACTGCACCT

CCAGTGCGTTGGACAGAAGG

GAAGAATCTGAGCTCCCGGTG

motif

TTGTTCAAGGCTTCCCCATGT

CCACTTTCACTGCTTTTACCCC

motif

CTGGACATGCTCTGGAGGAGA

GGAGTGAACACGGGATGCTT

necrosis

factor alpha
TNFR

Tumor

necrosis

factor receptor
CXCL-11

C-X-C
chemokine 11

CCL-23

C-C
chemokine

ligand

23
COX-2

Cyclooxygenase 2

GCTGTTCCCACCCATGTCAA

AAATTCCGGTGTTGAGCAGT

BAX

Bcl-2-associated X

CATGGGCTGGACATTGGACT

GGCAGCCCCCAACCAC

protein
IFNγ

Interferon gamma

TGGAAAGAGGAGAGTGACAGA

ACACTCTTTTGGATGCTCTGGT

IL-17a

Interleukin 17A

CCTTGGAATCTCCACCGCAA

GTGGTAGTCCACGTTCCCAT

iNOS

Inducible

GGACCCTGCAGACAGGC

TTCTTCACTGTGGGGCAAGG

CAGCAGGTCTGAGCTTGTCC

AGTGGGGGAGTTGCCCG

nitric

oxide synthase
cFLIP

Cellular

FLICE-

inhibitory protein
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Scientific, Waltham, MA) ELISAs were used to measure protein expression in
HREC and Müller cells. Cells were collected and processed as described above.
All samples were assayed in duplicate or triplicate per the manufacturer’s
instruction. Equal protein was loaded into all wells. The reported sensitivities of
these assays are 0.254 ng/mL for ICAM-1, 7.5 pg/mL for IL-8, 3.9 pg/mL for IL10, 1 pg/mL for IL-1β and 1.7 pg/mL for TNF-α.
Statistical analysis
All assays were carried out at least twice from three independent
experiments and the data are presented as mean + SD. Data were analyzed
by the Analysis of variance (ANOVA) test following by Fisher’s LSD test. P <
0.05 was considered to be statistically significant.
4.4 Results
IκBα levels are reduced in response to IL-1β/TNF-α, yet restored with IL-4
after HG exposure
Levels of IκBα, a regulatory protein that inhibits NF-κB, were assessed in
HREC and Müller cells after high glucose exposure and cytokine treatment over
time (Fig. 1). Regarding HREC, there was no difference in IκBα levels between
normal and high glucose. However, in the presence of pro-inflammatory
cytokines, IL-1β and TNF-α, IκBα was significantly downregulated early (30
minutes). These levels increased at 2h, but remained significantly reduced over
NG and HG treatment groups at 24h. In contrast, IL-4 treatment maintained
IκBα levels similar to controls.
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In contrast to HREC, HG reduced IκBα levels in Müller cells. However,
similar trends were observed after cytokine treatments, where pro-inflammatory
IL-1β and TNF-α significantly reduced IκBα at early time points, which then
appeared to peak at 2h and decrease at 24h (significant for TNF-α only). IL-4
treatment restored HG-induced downregulation of IκBα, which was significantly
higher than HG at 2h and both NG and HG at 24h.
Differential phosphorylation of NF-κB p65 subunits when exposed to high
glucose versus inflammatory cytokines in HREC and Müller cells
Next, we characterized the phosphorylation of NF-κB p65 subunits in
response to high glucose, pro-inflammatory NF-κB activators (TNF-α and IL-1β)
and anti-inflammatory IL-4 in HREC. As shown in Figure 22, high glucose
upregulated phosphorylation at five out of the eight tested p65 sites, including
Thr-254 (A), Ser-276 (B), Ser-468 (E), Ser-529 (F) and Thr-435 (H). No
differences were observed for sites Ser-281 (C), Ser-311 (D) or Ser-536 (G)
after exposure to high glucose only. When HREC were exposed to high glucose
in the presence of either IL-1β or TNF-α, all sites tested showed significantly
increased phosphorylation compared to normal glucose controls. Moreover,
both of these cytokines further enhanced NF-κB activation over high glucoseinduced effects at most of the time points tested. Additionally, IL-1β appears to
be a more potent stimulator of Ser-311 compared to TNF-α at 30 min after
treatment. On the contrary, anti-inflammatory cytokine IL-4 suppressed high
glucose-induced phosphorylation of p65 subunits sites Thr-254, Ser-281, and
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Thr-435. Although high glucose did not induce changes in Ser-281, Ser-311 or
Ser-536, IL-4 treatment reduced activation of NF-κB at 30 minutes for Ser-281
and at 2 and 24h for Ser-311 below basal levels observed with normal glucose.
No effect was observed with Ser-536. There was no indication that IL-4
treatment increased phosphorylation beyond the observed high glucoseinduced effects for sites Ser-276, Ser-468 and Ser-529.
The human Müller cell line, MIO-M1, indicated similar trends as observed
in HREC where not all sites resulted in increased phosphorylation with high
glucose exposure. As shown in Figure 23, p65 subunit sites Thr-254 (A), Ser281 (C), Ser-311 (D), Ser-468 (E) and Thr-435 (H) were activated due to high
glucose alone; while no differences in phosphorylation were observed for Ser276 (B), Ser-529 (F) and Ser-536 (G) compared to normal glucose controls.
Although, both Ser-529 and Ser-536 sites did reveal significantly increased
phosphorylation after treatment with IL-1β and TNF-α. Unlike HREC though, IL1β and TNF-α treatment did not appear to have as strong of an effect on Müller
cells; enhanced phosphorylation beyond high glucose-induced effects was
limited to Ser-468, Thr-254 (IL-1β only at 24h) and Ser-311 (TNF-α only at 10
and

30

min).

IL-4

treatment,

however,

significantly

downregulated

phosphorylation of NF-κB p65 at Thr-254, Ser-276, Ser-281, Ser-468 and Thr435 compared to high glucose. In addition, although phosphorylation levels of
Ser-276 did not change in response to high glucose or pro-inflammatory
cytokine treatment, IL-4 downregulated phosphorylation beyond normal
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glucose controls. Results of phosphorylation on different sites with high glucose
versus cytokines treatment are summarized in Table 2.
Effects of high glucose and cytokine treatment on transcription of
downstream genes associated with NF-κB activation in HREC and Müller cells
Transcription of selected genes known to be regulated by NF-κB as well as
pathogenic in DR was assessed after high glucose exposure and cytokine
treatment in both HREC and Müller cells. Analysis of gene expression in HREC
(Fig. 24) indicated that high glucose upregulated transcript levels of interleukin6 (IL-6) (D), IL-8 (E), IL-10 (F), TNF-α (G) and C-C motif chemokine ligand 23
(CCL23) (I). High glucose had no effect on the expression of ICAM-1 (A),
VCAM-1 (B), IL-1β (C), C-X-C motif chemokine 11 (CXCL11) (H),
cyclooxygenase-2 (COX-2) (J), or bcl-2 associated X protein (BAX) (K). When
high glucose exposure was combined with IL-1β treatment, transcription levels
of ICAM-1, VCAM-1, IL-1β, IL-6 (vs normal glucose only), IL-8, TNF-α, CXCL11,
CCL23 and COX-2 were significantly upregulated over both normal glucose and
high glucose alone. mRNA levels of IL-10 were lower than high glucose alone
at 30 min post-treatment with IL-1β, while BAX did not change from basal
expression levels. Treatment with TNF-α revealed similar trends compared to
IL-1β and resulted in upregulation of ICAM-1, VCAM-1, IL-1β, IL-6, IL-8, TNFα, CXCL11 and COX-2. Whereas, IL-10 expression was decreased compared
to high glucose only at 30 min and no differences were detected regarding
CCL23 or BAX compared to basal expression. Despite high glucose exposure,
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Table 2. Summarization of NF-κB p65 phosphorylation sites.
NF-κB p65
phosphorylation
sites

HREC

Main functions

HG

HG +
IL-1β or
TNF-α

Müller cells

HG +
IL-4

HG

HG +
IL-1β or
TNF-α

HG +
IL-4

p65
Thr-254
transactivation
↑
↑↑↑
↓
↑↑↑
↑↑↑
↓↓
[184]
CBP
recruitment,
system
Ser-276
inflammation
↑↑↑
↑↑↑
None
None
None
↓↓↓
[185, 186];
Translocation
of p65 [187]
Translocation
Ser-281
None
↑↑
↓
↑↑↑
↑↑↑
↓↓↓
of p65 [187]
IL-6
transcription
Ser-311
and CBP
None
↑↑↑
↓
↑
↑↑↑
None
recruitment
[188]
ICAM-1,
VCAM-1
Ser-468
↑↑↑
↑↑↑
None
↑
↑↑↑
↓
transcription
[189]
Translocation
Ser-529
↑
↑↑↑
None
None
↑↑↑
None
of p65 [190]
ICAM-1, IL-8
transcription
[191]; CBP
Ser-536
recruitment
None
↑↑↑
None
None
↑↑↑
↑
[192];
Translocation
of p65 [193]
p65
Thr-435
transactivation
↑↑↑
↑↑↑
↓
↑↑
↑↑↑
↓↓↓
[194]
↑/↓,↑↑/↓↓, ↑↑↑/↓↓↓ indicates P < 0.05, 0.01 and 0.0001, respectively, vs normal
glucose/high glucose controls. None = indicates no changes were observed. Results
were derived from the peak change observed among the different time points
examined.
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IL-4 treatment decreased mRNA levels for IL-6, IL-8 and TNF-α. No differences
were observed in ICAM-1, VCAM-1, IL-1β or BAX when compared to normal
glucose controls. In addition, IL-4 treatment upregulated IL-10 and CXCL11 at
24h, and COX-2 at 2h time points compared to high glucose only. High glucoseinduced upregulation of CCL23 mRNA remained unchanged after IL-4
treatment.
In Müller cells, high glucose exposure resulted in upregulation of mRNA
transcripts for a limited number of mediators (Fig. 25): TNF-α (F), interferongamma (IFNγ) and inducible nitric oxide synthase (iNOS) (J). Addition of proinflammatory IL-1β or TNF-α under high glucose conditions increased mRNA
levels for IL-1β (A), IL-6 (B), IL-8 (C), interleukin-17A (IL-17A) (E), TNF-α (F),
TNFR (TNF-α treatment only) (G), iNOS (J), COX-2 (K) and cellular FLICE
inhibitory protein (cFLIP) (L). Similar to HREC, CXCL11 (I) was exclusively
upregulated by TNF-α, not IL-1β, in Müller cells. IL-4 upregulated mRNA
expression of IL-10 (D) and COX-2, yet decreased expression of TNF-α, IFNγ,
CXCL11 and iNOS. No effect was observed regarding IL-6 or cFLIP expression
after IL-4 treatment.
Protein analysis of NF-κB regulated genes in HREC and Müller cells after
high glucose exposure and cytokine treatment
Based on mRNA expression, several genes were selected to further
analyze protein levels after 26 h of high glucose exposure and pro-/antiinflammatory cytokine treatments (Fig. 25). Consistent with mRNA results,
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protein levels of ICAM-1 (A), VCAM-1 (B), IL-1β (C), IL-8 (D), TNF-α (F) and
COX-2 (G) were similar in high and normal glucose. IL-10 (E), which was
downregulated, was the only molecule that did not show corresponding mRNA
expression and protein levels after high glucose exposure. When HREC were
exposed to high glucose and pro-inflammatory cytokine IL-1β or TNF-α, protein
levels were significantly elevated over both normal and high glucose for all
molecules (except IL-10) – including ICAM-1, VCAM-1, IL-1β, IL-8, TNF-α and
COX-2. As mentioned, IL-10 was significantly reduced in the presence of either
pro-inflammatory cytokine compared to normal glucose controls. On the other
hand, IL-4 treatment abrogated high glucose-induced changes in IL-8, TNF-α
and upregulated IL-10. Further, IL-4 treatment had no effect on ICAM-1, VCAM1 or IL-1β, which remained similar to basal levels observed in normal glucose.
Similar to mRNA expression, COX-2 protein levels were significantly elevated
with IL-4 treatment, but not as elevated after IL-1β or TNF-α treatments.
Protein levels were also examined at 24h in Müller cells exposed to high
glucose and cytokine treatments, as shown in Figure 27 for IL-1β (A), IL-8 (B),
IL-10 (C), TNF-α (D) and COX-2 (E). Exposure to high glucose had no effect on
IL-1β and COX-2 when compared to basal levels observed in normal glucose.
However, IL-8, TNF-α, and surprisingly IL-10 were significantly increased with
high glucose. As expected, treatment with IL-1β and TNF-α resulted in
significant increases of IL-1β, IL-8, TNF-α and COX-2 over both normal and
high glucose. IL-10, on the other hand, was significantly decreased compared
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to high glucose. These effects were consistently reversed following IL-4
treatment – reducing IL-8 and TNF-α to basal levels observed with normal
glucose exposure. IL-10, however, was further enhanced after IL-4 treatment
over high glucose.
4.5 Discussion
Phosphorylation is one of the prerequisite steps in NF-κB p65 activation. It
has been found to be highly important for recruitment of transcription factors
and subsequent binding of the p65 subunit with its target genes, as
demonstrated by various NF-κB p65 site specific studies [185-193, 195-198].
Although it has been shown over a decade ago that high glucose activates NFκB in both pericytes [199] and vascular smooth muscle cells [200], more recent
reports have indicated that NF-κB activation in RECs is rather due to paracrine
influences from other retinal cells such as Müller cells and pigment epithelial
cells [174]. As a result, we hypothesized that high glucose induces differential
phosphorylation of NF-κB in retinal cells. Specifically, we expected NF-κB p65
and downstream pathways associated with the pathogenesis of DR to be
differentially induced in RECs and Müller cells after high glucose exposure.
Beyond high glucose-induced activation of NF-κB, we also characterized the
effects of two potent NF-κB activators, IL-1β and TNF-α, both of which are
known to be produced early in the development of DR [115, 201, 202]. To this
end, we found similar trends between HREC and Müller cells in the
phosphorylation of 3 out of 8 sites of the p65 subunit – Thr-254, Thr-435 and
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Ser-468. High glucose significantly increased the phosphorylation of these
three sites compared to normal glucose. In addition, it appeared that highglucose induced phosphorylation of Ser-276 and Ser-529 was specific to HREC,
while phosphorylation of Ser-281 and Ser-311 was restricted to Müller cells.
Ser-536, on the other hand, was not affected by high glucose exposure in either
cell type. Moreover, pro-inflammatory cytokines were shown to be potent
activators of all p65 subunit sites, indicating an important role for Ser-536 in
particular regarding the canonical NF-κB pathway. Thus, we demonstrated that
selected NF-κB p65 sites were differentially influenced by high glucose in HREC
and Müller cells, and that the presence of pro-inflammatory cytokines IL-1β and
TNF-α exhibited a more widespread, robust effect on p65 phosphorylation sites.
The influence of high glucose versus pro-inflammatory cytokines on NF-κB
activity was further demonstrated by our studies of downstream target genes.
The complex nature of DR pathogenesis includes a wide spectrum of mediators,
such as advanced glycation end products (AGEs), ROS, protein kinase C (PKC)
pathway, polyol pathway and inflammatory pathways [203]. NF-κB is an
essential transcriptional regulator of numerous cytokines and is widely activated
by the aforementioned pathways. ROS is produced by retinal and inflammatory
cells during DR, which damages DNA and activates NF-κB [88]. AGEs, through
RAGE receptor activation, interact with the PKC pathway and influences NF-κB
activity [89, 90]. Upon activation by any of these pathogenic molecules related
to DR, NF-κB is able to stimulate further transcription of various inflammatory
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mediators that exacerbate the disease state in many aspects. This effect
includes upregulation of pro-inflammatory cytokines/chemokines IL-1β, TNF-α,
IL-6, IL-8 and monocyte chemotactic protein-1 (MCP-1) [91-95], iNOS [96];
COX-2 for the production of pro-inflammatory prostaglandins [97]; adhesion
molecules ICAM-1 and VCAM-1 [98]; and apoptotic molecules, Fas and Fas
ligand [99]. As such, based on an online NF-κB targeted gene list [204], NF-κB
regulated genes known to contribute to the pathogenesis of DR were selected
for further study. High glucose exposure led to the upregulation of proinflammatory molecules IL-8, IL-6, IFNγ, iNOS, and TNF-α, indicating that
hyperglycemia is capable of stimulating an inflammatory response in these cell
types. The fact that TNF-α was upregulated by high glucose alone in both cell
types underlines the detrimental effects of diabetes. As a major contributor to
the pathogenesis of DR, TNF-α mediates inflammation [205], regulates the
breakdown of the blood-retinal barrier [135], and directs apoptosis of retinal
residential cells [115]. As evidenced from pro-inflammatory cytokine treatments,
once TNF-α (or IL-1β) is present in the microenvironment, the cascade of
inflammatory events are exacerbated, which potentiates a state of chronic
inflammation within the retina. In fact, TNF-α and IL-1β exhibited a much more
robust effect on downstream inflammatory mediators compared to high glucose
alone. These findings agree with the trends observed from our NF-κB p65
phosphorylation studies, further indicating the importance of pro-inflammatory
cytokines in the early pathogenesis of DR, as high glucose appears to have a
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markedly reduced effect, in comparison, on these same key inflammatory
mediators.
Phosphorylation of Ser-311 by ζPKC has been associated with IL-6
transcription [188]. Both Ser-276 and Ser-311 phosphorylation has been found
to promote interaction with CREB, enhancing the NF-κB response [188, 195].
Ser-536 phosphorylation defines separate pathways of NF-κB activation of
canonical and non-canonical patterns, activating transcription of IL-8 and ICAM1, both of which are important for leukostasis activation [191]. Mutation of Ser536 prevents CBP recruitment [192]. Phosphorylation of Ser-529 and Ser-536
has been shown to be associated with translocation of NF-κB subunits [190,
193]. In the current study, we showed that Ser-311 and Ser-536 were not
responsive to high glucose exposure in HREC. Similarly, Ser-529 and Ser-536
remained unchanged in Müller cells. Yet these three sites were significantly
activated by inflammatory cytokines. It is possible that phosphorylation of these
sites are necessary for transcription of wide spectrum of NF-κB target genes.
Therefore, inhibiting phosphorylation on Ser-536, Ser-311 and Ser-529 could
potentially abrogate, in part, the translocation of NF-κB p65 into the nucleus
and influence the transactivation of p65, ultimately leading to a reduction in
transcriptional activity of target genes, as well.
Regulation of NF-κB is limited to the level of phosphorylation. IκBα inhibits
NF-κB by sequestering p65 in the cytoplasm. When phosphorylated,
ubiquitinated and then degradated, IκBα releases NF-κB p65 so that it can
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dimerize with p50, then translocate into the nucleus to trigger activation of the
downstream canonical NF-κB pathway [206]. Beyond the traditional view of
IκBα, recent reports have pointed out the existence of free IκBα in the cytoplasm
as an intrinsic unstable molecule, which is important for activation of NF-κB
itself and independent of IKK phosphorylation and ubiquitination [207]. This
adds to the complexity of the NF-κB pathway and promotes the possibility of
IκBα involvement in, not only the alternative NF-κB pathway, but also in an IKK
kinase and p65-p50-independent manner. Degradation of IκBα releases NF-κB
p65, which is a prerequisite for translocation of p65-p50. Although we showed
that pro-inflammatory cytokines significantly upregulate IκBα degradation in
both cell types, high glucose alone resulted in decreased IκBα levels in Müller
cells. These results suggest that Müller cells may be a more active responder
to high glucose conditions and perhaps have a larger role as a “decision maker”
in regards to the resultant inflammatory response observed during DR.
It was observed that IL-4 suppressed phosphorylation at Thr-254, Ser-276,
Ser-281 and Thr-435 in HREC and at Thr-254, Ser-276, Ser-281, Ser-468 and
Thr-435 in Müller cells. Although it has been reported that IL-4 induces NF-κB
p52 production by a PI3K and IB kinase dependent pathway [208], to our
knowledge, there is no established evidence regarding IL-4’s effect on
regulating phosphorylation of NF-κB p65. The fact that IL-4 suppressed the
phosphorylation of half of p65 sites in HREC and 5 out of 8 sites in Müller cells
demonstrates its protective effect by directly suppressing NF-κB p65 activity in
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high glucose. mRNA and protein results indicated that IL-4 effectively reduced
IL-6, IL-8 and TNF-α in HREC and TNF-α, IFNγ, CXCL-11 and iNOS in Müller
cells. Despite that this was somewhat expected since IL-4 significantly
suppressed multiple NF-κB p65 phosphorylation sites, IL-4 treatment also
upregulated IL-10 and COX-2. Whether this is a direct consequence of the
inhibitory effect of IL-4 on p65 phosphorylation needs to be further tested, but it
is thought that the regulatory effect of this anti-inflammatory cytokine on NF-κB
works synergistically with its traditional PI3K and mitogenic signaling [209]. In
Müller cells, IL-4 suppressed IL-8 protein levels, indicating that a translational
effect as this was not reflected at the mRNA level. Previous results have
indicated that IL-4 enhances IL-10 gene expression in the absence of TCR
engagement [210]. In both types of cells, we demonstrated that IL-4 is capable
of enhancing IL-10, possibly promoting an anti-inflammatory response in this
situation. Since IL-10 has the ability to inhibit the expression of IL-8 [211] and
regulates TNF-α signaling [212], it is possible that suppression of IL-8 and TNFα by IL-4 is partially carried out by regulation of IL-10 through an autocrine
manner in both cell types. This could be greatly beneficial as TNF-α is one of
the major pro-inflammatory mediators during the pathogenesis of DR. This is
also very comparable to our previous research indicating an anti-inflammatory
effect of vasoactive intestinal peptide in suppressing intracellular TNF-α levels
[213]. It is also important to note that IL-4 enhanced IκBα levels in Müller cells,
which could also contribute to inhibition of NF-κB p65 phosphorylation and
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subsequent expression of NF-κB target genes. In addition, the fact that IL-4
promoted expression of COX-2 in both cell types could be associated with COX2 derived prostanoids, which are important at low levels in the development of
a “healthy” immune response.
It is important to note that cytokine induced phosphorylation of NF-κB p65
was not always sustained, but instead fluctuated over time; some changes
occurred earlier, while others happened later. For example, the suppressive
effect of IL-4 regarding phosphorylation of NF-κB p65 in HREC were mostly
observed at later time points (2 and 24 hours), whereas in Müller cells, some
changes were observed early and lasted through 24 hours. Again, this could be
partially derived from IL-4 induced upregulation of IL-10, which has been
demonstrated to suppress NF-κB activity through regulation of p50 [214].
Upregulation of IκBα in Müller cells by IL-4 could possibly inhibit
phosphorylation of p65, as well. In contrast, as expected, traditional canonical
NF-κB pathway activators IL-1β and TNF-α evoked phosphorylation activity
mostly at earlier time points.
The current study is the first one demonstrating the suppressive effect of
IL-4 on the phosphorylation of NF-κB p65. Whether IL-4 is capable of inhibiting
IL-1β and TNF-α evoked inflammatory response in high glucose cultured retinal
residential cells warrants further investigation. Although the detailed regulatory
chains between different NF-κB p65 sites and downstream genes and protein
expression of related inflammatory mediators needs further study, the fact that
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IL-4 not only suppressed NF-κB target inflammatory genes, but also inhibited
phosphorylation of NF-κB at different sites in different cells provides us another
avenue for treatment against the pathogenesis of DR. In addition, since NF-κB
p65 phosphorylation is one of the most important events during high glucose
induced pathogenic changes in the retina, in this study, it is important to
understand how NF-κB p65 phosphorylation is promoted with high glucose
versus cytokine exposure. Again, pro-inflammatory cytokines significantly
exacerbated high glucose induced NF-κB activity, demonstrating their larger
role in driving NF-κB phosphorylation and expression of target genes compared
to high glucose conditions alone.
4.6 Conclusions
In summary, high glucose-induced site specific differential phosphorylation
of NF-κB p65 in HREC and Müller cells were characterized and demonstrated
the importance of pro-inflammatory cytokines in exacerbating the response. We
also demonstrated that IL-4 effectively inhibited high glucose-induced NF-κB
phosphorylation at multiple p65 sites in HREC and Müller cells. The current
study is the first to characterize high glucose-induced NF-κB p65
phosphorylation and reveal IL-4’s regulatory effect on this activity. As such, it
underscores the importance of recognizing the differential influence of
hyperglycemic conditions between multiple retinal cell types and that the
observed effects go beyond a single phosphorylation site on NF-κB p65 subunit.
These findings are important in understanding the pathologic events associated

- 94 -

with DR. NF-κB activation is a major event associated with high glucoseinduced changes in the retina; however, we can conclude from this study that
understanding how NF-κB is activated in each cell type is important since cell
types and phosphorylation sites are differentially responsive to both high
glucose and inflammatory mediators.
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Figure 21. Degradation of IκBα in HREC vs Müller cells when cultured in high
glucose with cytokine treatments. HREC and Müller cells were cultured under
normal glucose (NG, 5mM) and high glucose (HG, 25mM) conditions followed by
TNF-α, IL-1β versus IL-4 treatment for 10 minutes (Müller cells only), 30 minutes, 2
hours and 24 hours. Protein levels of IκBα in HREC (A) and IκBα in Müller cells (B)
were detected by Western blot. Data shown are representative of 5 independent
experiments in duplicate and are expressed as mean ± SD. *P < 0.05 vs NG, #P <
0.05 vs HG.
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Figure 22-1. Differential site-specific phosphorylation of NF-κB p65 after high
glucose exposure and pro- versus anti-inflammatory cytokine stimulation in
HREC. HREC were cultured under normal glucose (NG, 5mM) and high glucose
(HG, 25mM) conditions followed by TNF-α, IL-1β versus IL-4 treatment for 30
minutes, 2 hours and 24 hours. Protein levels of phosphorylated p65 Thr-254 (A),
phosphorylated p65 Ser-276 (B), phosphorylated p65 Ser-281 (C) and
phosphorylated p65 Ser-311 (D) were detected by Western blot. Data shown are
representative of 5 independent experiments in duplicate and are expressed as
mean ± SD. *P < 0.05 vs NG, #P < 0.05 vs HG.
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Figure 22-2. Differential site-specific phosphorylation of NF-κB p65 after high
glucose exposure and pro- versus anti-inflammatory cytokine stimulation in
HREC. HREC were cultured under normal glucose (NG, 5mM) and high glucose
(HG, 25mM) conditions followed by TNF-α, IL-1β versus IL-4 treatment for 30
minutes, 2 hours and 24 hours. Protein levels of phosphorylated p65
phosphorylated p65 Ser-468 (E) and phosphorylated p65 Ser-529 (F),
phosphorylated p65 Ser-536 (G) and phosphorylated p65 Thr-435 (H) were
detected by Western blot. Data shown are representative of 5 independent
experiments in duplicate and are expressed as mean ± SD. *P < 0.05 vs NG, #P <
0.05 vs HG.
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Figure 23-1. Site-specific differential phosphorylation of NF-κB p65 in Müller
cells after high glucose exposure and pro- versus anti-inflammatory cytokine
stimulation. Müller cells were cultured under normal glucose (NG, 5mM) and high
glucose (HG, 25mM) conditions followed by TNF-α, IL-1β versus IL-4 treatment for
10 minutes, 30 minutes, 2 hours and 24 hours. Protein levels of phosphorylated p65
Thr-254 (A), phosphorylated p65 Ser-276 (B), phosphorylated p65 Ser-281 (C) and
phosphorylated p65 Ser-311 (D) were detected by Western blot. Data shown are
representative of 5 independent experiments in duplicate and are expressed as
mean ± SD. *P < 0.05 vs NG, #P < 0.05 vs HG.
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Figure 23-2. Site-specific differential phosphorylation of NF-κB p65 in Müller
cells after high glucose exposure and pro- versus anti-inflammatory cytokine
stimulation. Müller cells were cultured under normal glucose (NG, 5mM) and high
glucose (HG, 25mM) conditions followed by TNF-α, IL-1β versus IL-4 treatment for
10 minutes, 30 minutes, 2 hours and 24 hours. Protein levels of phosphorylated p65
Ser-468 (E), phosphorylated p65 Ser-529 (F), phosphorylated p65 Ser-536 (G) and
phosphorylated p65 Thr-435 (H) were detected by Western blot. Data shown are
representative of 5 independent experiments in duplicate and are expressed as
mean ± SD. *P < 0.05 vs NG, #P < 0.05 vs HG.
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Figure 24-1. mRNA expression levels of NF-κB regulated pathogenic genes
after high glucose exposure and pro- versus anti-inflammatory cytokine
treatment in HREC. HREC were cultured under normal glucose (NG, 5mM) and
high glucose (HG, 25mM) conditions followed by TNF-α, IL-1β versus IL-4 treatment
over time. mRNA levels of ICAM-1 (A), VCAM-1 (B), IL-1β (C), IL-6 (D), IL-8 (E) and
IL-10 (F) were detected by real-time RT-PCR. Data shown are representative of 5
independent experiments in duplicate and are expressed as mean ± SD. *P < 0.05
vs NG, #P < 0.05 vs HG.
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Figure 24-2. mRNA expression levels of NF-κB regulated pathogenic genes
after high glucose exposure and pro- versus anti-inflammatory cytokine
treatment in HREC. HREC were cultured under normal glucose (NG, 5mM) and
high glucose (HG, 25mM) conditions followed by TNF-α, IL-1β versus IL-4 treatment
over time. mRNA levels of TNF-α (G), CXCL-11 (H), CCL-23 (I), COX-2 (J) and BAX
(K) were detected by real-time RT-PCR. Data shown are representative of 5
independent experiments in duplicate and are expressed as mean ± SD. *P < 0.05
vs NG, #P < 0.05 vs HG.
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Figure 25-1. mRNA expression of NF-κB regulated pathogenic genes under
high glucose conditions and cytokine polarization in Müller cells. Müller cells
were cultured under normal glucose (NG, 5mM) and high glucose (HG, 25mM)
conditions followed by TNF-α, IL-1β versus IL-4 treatment over time. mRNA levels
of IL-1β (A), IL-6 (B), IL-8 (C), IL-10 (D), IL-17a (E) and TNF-α (F) were detected
by real-time RT-PCR. Data shown are representative of 5 independent experiments
in duplicate and are expressed as mean ± SD. *P < 0.05 vs NG, #P < 0.05 vs HG.
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Figure 25-2. mRNA expression of NF-κB regulated pathogenic genes under
high glucose conditions and cytokine polarization in Müller cells. Müller cells
were cultured under normal glucose (NG, 5mM) and high glucose (HG, 25mM)
conditions followed by TNF-α, IL-1β versus IL-4 treatment over time. mRNA levels
of TNFR (G), IFNγ (H), CXCL-11 (I), iNOS (J), COX-2 (K) and cFLIP (L) were
detected by real-time RT-PCR. Data shown are representative of 5 independent
experiments in duplicate and are expressed as mean ± SD. *P < 0.05 vs NG, #P <
0.05 vs HG.
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Figure 26-1. Protein levels of select NF-κB regulated inflammatory mediators
in HREC after high glucose exposure and pro- versus anti-inflammatory
cytokine polarization. HREC were cultured under normal glucose (NG, 5mM) and
high glucose (HG, 25mM) conditions followed by TNF-α, IL-1β versus IL-4 treatment
for 24 hours. Protein levels of ICAM-1 (A), VCAM-1 (B), IL-1β (C), IL-8 (D), IL-10
(E), TNF-α (F) and COX-2 (G) were detected by ELISA or Western-blot. Data shown
are representative of 5 independent experiments in duplicate and are expressed as
mean ± SD. *P < 0.05 vs NG, #P < 0.05 vs HG..
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Figure 26-2. Protein levels of select NF-κB regulated inflammatory mediators
in HREC after high glucose exposure and pro- versus anti-inflammatory
cytokine polarization. HREC were cultured under normal glucose (NG, 5mM) and
high glucose (HG, 25mM) conditions followed by TNF-α, IL-1β versus IL-4 treatment
for 24 hours. Protein levels of IL-10 (E), TNF-α (F) and COX-2 (G) were detected
by ELISA or Western-blot. Data shown are representative of 5 independent
experiments in duplicate and are expressed as mean ± SD. *P < 0.05 vs NG, #P <
0.05 vs HG..
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Figure 27. Protein levels of select NF-κB regulated inflammatory mediators in
Müller cells exposed to high glucose with cytokine treatment. Müller cells were
cultured under normal glucose (NG, 5mM) and high glucose (HG, 25mM) conditions
followed by TNF-α, IL-1β versus IL-4 treatment for 24 hours. Protein levels of IL-1β
(A), IL-8 (B), IL-10 (C), TNF-α (D) and COX-2 (E) were detected by ELISA or
Western-blot. Data shown are representative of 5 independent experiments in
duplicate and are expressed as mean ± SD. *P < 0.05 vs NG, #P < 0.05 vs HG.
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CHAPTER 5 “RETINAL ISCHEMIA-REPERFUSION INJURY MODEL:
A CONTRAST IN PATHOGENIC RESPONSES BETWEEN C57BL/6J
VERSUS BALB/cJ MICE”
5.1 Abstract
Retinal ischemia has been shown to contribute to the pathogenesis
observed during diabetic retinopathy (DR). As a result, the retinal ischemiareperfusion (I/R) injury model has been useful in studying neuronal and
vascular damage to the retina – damage that is similarly observed during the
development of DR. Notably, murine models of both I/R and DR tend to be
carried out in C57BL/6J (B6) mice, which have been classified as type 1dominant responders. In bacterial keratitis models, previous study has
established that B6 mice are susceptible, while BALB/c mice (classified as type
2-dominant) exhibit a resistant phenotype [215]. Although the cornea and retina
are quite different, we questioned whether the type 1/type 2 inflammation
paradigm could be extrapolated to events associated with the pathogenesis of
I/R and related DR. I/R injury was induced in both B6 and BALB/c mice by
cannulating the anterior chamber of one eye of anesthetized animals. The other
eye served as control. Retinas were collected after 2 days and stained by
hematoxylin and eosin (H/E) to examine neuronal differences. After 10 days,
retinal microvasculature was isolated from whole retinas to quantitate
differences in degenerated capillaries. Retinal lysates were also processed for
protein analyses of key inflammatory mediators known to play a role in the
development of DR. Overall, strain specific differences were observed between
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B6 and BALB/c mice in response to I/R injury. Although both strains showed
signs of retinal injury, more damage was observed in B6 mice as detected by
reduced retinal thickness, increased microvascular degeneration and elevated
inflammatory mediators. These data suggest that B6 and BALB/c mice respond
to I/R injury differently, which has implications not just for retinal ischemia, but
for the development of DR. Elucidating these differences both offers potential
therapeutic points of intervention and impacts the current modeling system
used to study retinal diseases, such as DR.
5.2 Introduction
Ischemia-reperfusion (I/R) injury induces the production of free radicals
resulting in local inflammation and tissue damage. At the reperfusion stage,
restoration of the blood supply leads to accumulation of oxygen radicals, further
causing oxidative stress such as lipid peroxidation [107, 108], damaging
residential cells and stimulating secretion of pro-inflammatory cytokines.
Production of IL-8 and adhesion molecules chemoattracts neutrophils and
macrophages into the injured tissue. Accumulation of inflammatory cells at the
I/R site elicits further production of reactive oxygen species (ROS), cytokines
and chemokines, exacerbates local inflammation in the damaged tissue.
Regarding eyes, retinal I/R surgery, by increasing intra-ocular pressrure,
was demonstrated to induce pathophysiological changes that are similarly
observed in diabetic retinopathy (DR) and glaucoma [112]. The ROS
scavenging system is severly impaired in DR, resulting in upregulated ROS
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concentrations in the retina. This is comparable to the accumulation of ROS
and its resultant upregulation of inflammation along with vascular damage after
I/R. Earlier studies found that I/R promoted nitric oxide neurotoxicity, resulting
in retinal neurodegeneration [113, 216]. This effect is also demonstrated by
reduction of amplitude of a-wave and b-wave based on electroretinogram (ERG)
[217]. In addition, studies in rodent models demonstrated vascular
degeneration after retinal I/R surgery as detected by acellular retinal capilaries
and inflammatory markers inducible nitric oxide synthase (iNOS) and
cyclooxygenase-2 (COX-2) [114]. Retinal apoptosis, breakdown of the bloodretinal barrier (BRB), and excerbated retinal microvascular leakage were also
recorded following induced intraocular pressure and reperfusion [218]. Thus,
the retinal I/R model is a reliable tool to mimic neurodegeneration,
microvasuclar degeneration and inflammation associated with DR.
In DR pathogenesis, upregulation of inflammatory markers such as iNOS,
COX-2, intracellular adhesion molecule-1 (ICAM-1), vascular endothelial
growth factor (VEGF), NF-κB, interleukin-1 beta (IL-1β) not only emphasizes
the important role of inflammation, but also implies its crossing-talking with
other pathogenic pathways [8]. Similarly, increased leukocyte rolling and
accumulation at retinal microvasculature was observed in a rat model of I/R
[219]. There is significant upregulation of inflammatory markers following retinal
I/R surgery as well since it induces similar microvascular ischemia to DR; tumor
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necrosis factor-alpha (TNF-α), IL-1β, ICAM-1 and interleukin-6 (IL-6) were all
found to be upregulated in rats after retinal I/R surgery [220].
The type 1 versus type 2 inflammation paradigm emphasizes the cytokine
function and denotes production by all cell types rather than CD4+ T Cells as
the sole source of these mediators [221]. Type 1-dominance is usually
characterized by strong pro-inflammatory activation, accompanied by elevated
and sustained pro-inflammatory cytokine levels that exacerbate inflammation
and can develop into chronic inflammation state, if left uncontrolled. In type 2
inflammation, anti-inflammatory response dominates, limiting inflammation with
subsequent inflammation resolution by pro-resolving pathway. In this regard,
the current study is focusing on the general inflammatory acitivties in the retina,
in which residential retinal cells and inflammatory cells both partipate in by
secreting cytokines that drive inflammation further. Despite all the effort has
been put into studies of inflammation in DR, little is known regarding the infleuce
of the type 1/type 2 balance on DR. BALB/c (resistant, type 2 dominant) and
C57BL/6J (B6) (susceptable, type 1 dominant) type mice have proven as very
suitable tools in investigating type 1/type 2 inflammation [40, 43, 222]. In this
study, we sought to investigate the difference in the pathogenic response
related to type 1 versus type 2 inflammation using a model of retinal I/R. We
expect these findings will define a role for inflammation in the retinal response
to ischemic conditions, which is a characteristic event associated with the
development of DR.
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5.3 Methods
Intraocular Ischemia-Reperfusion
All mouse experiments were approved by the Institutional Animal Care and
Use Committee at Wayne State University (Protocol# 11-08-14). I/R was carried
out in 7 weeks old male B6 and BALB/c mice purchased from Jackson
Laboratories. The anterior chamber of one eye was cannulated with a 30-gauge
needle attached to a line infusing normal saline. Intraocular pressure (IOP) was
measured by a handheld tonometer (TONO Pen; Medtronic Solan, Jacksonville,
FL) in mouse eyes, and pressure in the eye regulated to 80-90 mm Hg with a
pressure infuser (Infu-surg; Ethox Corp., Buffalo, NY). The other eye of the
same animal servedas a control. After 90 min of ischemia, the needle was
withdrawn, IOP was normalized, and reflow of the retinal circulation was
documented visually [114]. Ocular tissue was harvested at 2 and 10 days postinjury for analyses as described below.
Neuronal analyses
At 2 days post-I/R injury, whole eyes were removed, followed by a 30 min
fixation in 4% paraformaldehyde. Ten-μm retinal sections were stained using
for hematoxylin and eosin, then visualized by light microscopy for morphometry
of retinal thickness. Photomicrographs were assessed for retinal thickness and
the number of cells in the ganglion cell layer were quantitated. The thickness of
the retina and the cell count was measured using Invitrogen EVOS FL Auto Cell
Imaging System (Invitrogen, Carlsbad, CA).
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Vascular analyses
Eyes were enucleated at 10 days after I/R exposure suspended in 10%
buffered formalin for 5 days, and the retina was dissected in 40U/mL elastase
solution (Merck Millipore, Burlington, MA). The retinal vascular tree was dried
onto a glass slide and stained with hematoxylin-periodic acid-Schiff.
Degenerate

capillaries, identified as acellular capillary-sized tubes, were

counted [223] in mid-retina in 5 fields. Degenerate capillaries were excluded if
their average diameter was less than 20% of surrounding healthy capillaries
[224].
ELISA
IL-1β and TNF-α ELISA kits (R&D Systems, Minneapolis, MN) were used
to measure protein expression in whole retinal lysates. Retinal extracts were
prepared by sonication. All samples were assayed in duplicate or triplicate per
the manufacturer’s instruction. Equal protein was loaded into all wells. The
reported sensitivities of these assays are 4.8 pg/mL for IL-1β and 7.21 pg/mL
for TNF-α.
Western Blotting
Retinal lysates were collected and processed as described above. Equal
amount of total proteins were then separated on 4–20% tris-glycine gels
(Invitrogen, Carlsbad, CA) and transferred to nitrocellulose membranes. After
blocking membranes in TBST (10 mM Tris-HCl buffer, pH 8.0, 150 mM NaCl,
0.1% Tween 20) and 5% (w/v) BSA at r.t. for 60 min, membranes were
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incubated overnight at 4°C with antigen-specific primary antibodies. The
primary antibodies were used as follows: anti-NF-κB p65 (phospho Ser-536),
anti-ICAM-1 (Cell Signaling Technology, Danvers, MA); anti-VEGF (Abcam,
Cambridge, United Kingdom); anti-COX-2, and anti-β-actin (Santa Cruz, Santa
Cruz, CA). Blots were then incubated with species-specific HRP-conjugated
secondary antibodies for 2h at r.t. Proteins were visualized by incubation with a
chemiluminescence substrate kit (Thermo Fisher Scientific, Waltham, MA).
Western blot images were collected (Azure Biosystem C500, Dublin, CA) and
target protein expression was quantified (Image Studio Lite software) after
normalizing to β-actin. One representative blot is shown.
Statistical analysis
All assays were carried out at least twice from five independent experiments
and the data are presented as mean + SD. Data were analyzed by the Analysis
of variance (ANOVA) test following by Fisher’s LSD test. P < 0.05 was
considered to be statistically significant.
5.4 Results
Loss of retinal thickness and retinal ganglion cells as observed in BALB/c
and B6 mice following I/R surgery
To begin investigating whether BALB/c mice are more resistant than B6 to
retinal damage, we first measured I/R induced retinal neurodegenreration.
Figure 28 shows significant retinal thining of retina in both B6 (B) and BALB/c
mice (D), compared to non-injured control mice (A &C, respectively). Retinal
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thickness loss is significantly less in BALB/c I/R mice compared to B6 I/R mice.
This is supported by more ganglion cells observed in BALB/c I/R mice.
BALB/c mice exhibit reduced microvascular damage in response to I/R
compared to B6
Next, we sought to find out if I/R-induced retinal microvascular damage
could also be limited in these type 2-dominant mice. As shown in Figure 29,
significantly fewer degenerated acellular capillaries were observed in BALB/c
mice when compared to B6 mice following retinal I/R surgery.
Retinal I/R induced inflammatory activities are reduced in type 2 dominant
BALB/c mice
It is important to determine whether retinal I/R induced local inflammation
is different in type 2 dominant BALB/c mice versus type 1 dominant B6 mice.
As shown in Figure 30, IL-1β (A), TNF-α (B), ICAM-1 (C), VEGF (D),
phosphorylated NF-κB p65 at Ser-536 (F) have similar trends: I/R-induced
upregulation of these molecules is significantly lower in BALB/c mice compared
to B6 mice. Control mice of BALB/c have higher expression of COX-2 than that
of B6 mice. I/R upreuglated levels of COX-2 in B6 mice yet downregulated it in
BALB/c mice (E).
5.5 Discussion
For the recent decade, inflammation been indentified as one of the
important therapeutic target for DR [116, 225, 226]. In vitreous fluid of eyes of
patients with progressive diabetic retinopathy (PDR), elevated levels of
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various cytokines have been detected; several of them are potent
inflammatory mediators, including IL-1β, TNF-α, IL-6, IL-8 and macrophage
chemotatic protein-1 (MCP-1) [227, 228]. As key players in local inflammation
and homeostasis, the relative balance between type 1 pro-inflammatory
cytokines (IFN-γ, TNF-α, IL1β) and type 2 anti-inflammatory cytokines (IL-4,
IL-10) is expected to be essential in DR pathogenesis. The major goal of this
study is to determine whether a predominately anti-inflammatory environment
in type 2 models would build a “resistant” force against inflammatory
mediators of DR. Using a Pseudomonas aeruginosa-induced bacterial
keratisis model, previous work in our lab has demonstrated the benefits of
type 2 BALB/c mice in terms of local homeostasis and reconsitution after
infection [42]. Thus, we expected BALB/c mice to be at least partially resistant
to I/R-induced DR-like inflammation, as well.
NF-κB is a pivotal regulator of general inflammation, and for the recent
decade, was demonstrated to be a master transcription factor protein family to
promote transcription of pathogenic molecules for DR as it could not only be
upregulated by reactive oxygen species (ROS) [88] and advanced glycation
endpucts (AGEs) [89, 90], but also further stimluates production of IL-1β, TNFα, IL-6, IL-8, MCP-1, iNOS, COX-2, ICAM-1, vascular adhesion molecule-1
(VCAM-1), Fas and Fas ligand [91-99]. In type 2 dominant BALB/c mice,
phosphorylation at NF-κB p65 ser-536 was significantly downregulated in
comparison to B6 mice in current study. Since phosphorylation of NF-κB p65 is
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prerequisite to its translocation and subsequent binding to target genes, and
p65 is the most important activator in NF-κB family, this result implicates that,
in type 2 dominant BALB/c mice, the ability of NF-κB to promote transcription
of target genes is strongly compromised. This correlates with the observed
changes in IL-1β, TNF-α and ICAM-1 protein levels since they are known to be
regulated by NF-κB. Given IL-1β and TNF-α are hallmark inflammatory
molecules in DR-induced inflammation and canonical activators of NF-κB, the
fact that they were downregulated in I/R-induced type 2 dominant BALB/c mice
indicates less extent of inflammatory activity. In a streptozotocin-induced DR
model, inhibition of ICAM-1 decreased leukotasis and vascular leakage [22].
Thus, less expression of ICAM-1 in BALB/c mice compared to B6 mice
suggests that these animals may have relatively fewer leukocyte docking and
transmigration activities and reduced local inflammation in response to I/R injury.
On the other hand, upregulation of COX-2 and its induced production of
prostaglandins were reported in DR models [27, 229]. As the key enzyme for
production of pro-inflammatory lipid mediators, COX-2 promotes pathogenesis
of DR by producing prostaglandins. We observed a higher level of basal COX2 in BALB/c mice, yet this level goes down with retinal injury. It is possible that
decreased COX-2 expression will lead to compromised production of
prostaglandins in BALB/c mice, although this needs further study to confirm.
The initial genesis of vision loss in DR has long-time been attributed to
breakdown of blood-retinal barrier and increased retinal microvascular
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permeability [230]. There are two major types of cells in the retinal
microvascular endothelium: pericytes and endothelial cells. Based on animal
study, pericytes begin to degenerate before the disappearance of endothelial
cells in DR, leaving thin, acellular capillaries behind [231]. As a result, the
ischemic retina starts to build more capillaries in an attempt to restore the blood
supply, by secreting VEGF, which stimulates angiogenesis [232]. To this end,
we observed fewer degenerated capillaries in the vascular analyses, indicating
BALB/c mice are more resistant to microvascular degeneration. Additionally,
BALB/c mice express lower levels of VEGF following I/R surgery, implying less
pathogenesis of microvasculature [233]. While DR has been traditionally
considered to be a microvascular eye complication, recently it is demonstrated
to be more of a neurovascular event. Experts have concluded that
neurodegeneration takes place very early during pathogenesis of DR,
predicting and contributing to later microvascular changes [234]. As we
observed much less neurodegeneration in BALB/c mice as well, it is concluded
that BALB/c mice, with a type 2-dominant inflammatory response, are resistant
to DR-like neurodegeneration and microvascular degeneration.
Even though steroids and nonsteroidal anti-inflammatory drug (NSAID)
have been applied to treat ocular inflammatory coditions [235], very limited
effort has been put into investigating anti-inflammatory and pro-resolving
mechanism in DR disease progression. Current anti-inflammatory treatments
are also expected to deliver unwanted consequence and may require
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combination usage. The low efficacy of anti-inflammatory treatments might be
attributed to insuffient resolution of inflammation. This study, in an effort to
unravel more myth behind pathogenesis of inflammation in DR, demonstrates
Type 2 dominant immune activity is able to resist I/R induced DR like
inflammatory

stimulation

and

neurovascular

degeneration.

Whether

neurovascular changes in BALB/c mice is direct consequece of robust antiinflammatory activities in Type 2 type immunity needs further study. However,
the fact we observed significantly less expression of pro-inflammatory cytokines
have provided another insight for the interventation point of treatments on DR.
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Figure 28. Neuronal analysis of BALB/c and B6 retinas after I/R. Panels A and
C show the contralateral eyes (ctrl) of B6 and BALB/c mice, respectively. Panels B
and D show eyes 2 days after I/R surgery in B6 and BALB/c, respectively. Bar
graphs below quantitative changes in retinal thickness (left) and cell numbers
(right). Data shown are representative of 5 independent experiments and are
expressed as mean ± SD. *P < 0.05 indicates statistical significance.
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Figure 29. Vascular analysis of BALB/c and B6 mice after I/R. Panels A and C
show the contralateral eyes (ctrl) of B6 and BALB/c mice, respectively. Panels B
and D show eyes 10 days after I/R surgery in B6 and BALB/c, respectively.
Quantification of acellular capillaries is presented in the bar graph. Data shown are
representative of 5 independent experiments and are expressed as mean ± SD. *P
< 0.05 indicates statistical significance.
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Figure 30. Selected inflammatory markers as detected in retinas of BALB/c
and B6 mice in response to I/R. Retinal lysates were processed after 10 days of
I/R injury. Protein levels of IL-1β (A), TNF-α (B), ICAM-1 (C), VEGF (D), COX-2 (E)
and phosphorylated NF-κB at ser-536 were detected by ELISA or Western-blot.
Data shown are representative of 5 independent experiments and are expressed
as mean ± SD. *P < 0.05 indicates statistical significance.
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The general purpose of these studies is to investigate inflammation in
diabetic retinopathy in an effort to identify key intervention points to develop as
treatments. Firstly, we showed that the neuropeptide VIP displayed protective
immunoregulatory effects on retinal endothelial cells cultured under high
glucose conditions. This effect was carried out, in part through the VPAC2
receptor.
Next, we studied the β-adrenergic receptor agonist, Compound 49b, and its
effect on the pro-resolving RvD1 pathway. Compound 49b was previously
shown to suppress both inflammatory and apoptotic responses in DR. We
demonstrated that Compound 49b rescued the high glucose-induced decrese
in RvD1 and its receptors in diabetic animals and retinal endothelial cell culture,
by upregulating 15-LOX enzyme expression.
We also studied the phosphorylation of NF-κB p65 in two retinal cell types
exposed to high glucose. High glucose conditions stimulated phosphorylation
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of NF-κB p65 at Thr-254, Ser-276, Ser-468, Ser-529, Thr-435 in retinal
endothelial cells and Thr-254, Ser-281, Ser-311, Ser-468, Thr-435 in Müller
cells. IL-4, an anti-inflammatory cytokine, suppressed phosphorylation at Thr254, Ser-311, Thr-435 in retinal endothelial cells and Thr-254, Ser-276, Ser-281,
Thr-435 in Müller cells. Futhermore, IL-4 also reduced related downstream NFκB regulated molecules IL-8, TNF-α, and upregulated IL-10.
The influence of type 1 vs type 2 immune backgrounds on DR-related
damage using a model of retinal ischemia-reperfusion was studied in C57BL/6
and BALB/c mice. Notably, both neuronal and vascular degeneration were
significantly less in BALB/c compared to B6 mice. Furthermore, key
inflammatory molecules IL-1β, TNF-α, NF-κB, ICAM-1 and VEGF were
downregulated in BLAB/c mice, as well.
Collectively, we have shown the extensive role that inflammation plays in
diabetic retinopathy pathogenesis. More importantly, the innate type 1/type 2
paradigm suggests that the potential of anti-inflammatory treamtents and proresolving lipid mediators in suppressing pathogenesis of DR. We expect our
findings in pathogenesis of inflammation to contibute to development of antiinflammatory and pro-resolving treatments for diabetic retinopathy.
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